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CHAPTER 1 – INTRODUCTION 
1.1. Antibacterial resistance  
 
Since the discovery of penicillin over 70 years ago,1-2 many antibiotics have been 
developed. Antibiotics have improved public health and human well-being, which has 
also led to widespread overuse.3 Some commonly used antibiotics and their class 
designations are listed in Table 1.1. There are antibiotics that target cell wall synthesis 
(e.g., penicillins),1-2 folate synthesis (e.g., sulfonamides),4 DNA topoisomerases or DNA 
gyrases (e.g., fluoroquinolones),5 and protein synthesis (e.g., tetracyclines,6-7 
macrolides,8 and aminoglycosides9-12). Structures of some antibiotics from each class 
are shown in Figure 1.1. Many drugs that target protein synthesis inhibit the elongation 
step,3 but numerous modes of action exist. Some mechanisms involving the bacterial 
ribosome include binding to the 30S subunit10-11, 13-14 and inhibiting tRNA binding,6 or 
disrupting translocation8, 15 and tRNA recognition by interacting with the peptidyl 
transferase center (PTC) or the decoding region (A site).15 Macrolides, lincosamides, 
and streptogramin A (MLS) are known to target the PTC region of the 50S subunit and 
block the peptide exit tunnel.8, 15-16 Aminoglycosides are known to interact with the 
decoding region of the 30S subunit and interfere with tRNA selection.10-11, 14, 17  
 
 
Table 1.1. Major antibiotic classes, examples, and their targets  
 classes examples  target 
 penicillins1-2 penicillin, amoxicillin peptidoglycan cell wall synthesis 
 tetracyclines6-7 tetracycline, doxycycline A site of 30S subunit 
 macrolides8 azithromycin, erythromycin peptide exit tunnel 
 
aminoglycosides9-12 
neomycin, kanamycin, 
paromomomycin 
A site of 30S subunit 
 sulfonamides4 prontosil, sulfafurazole dihydroopteroate synthetase 
 fluoroquinolones5 ciprofloxacin, levofloxacin DNA topoisomerase, DNA gyrase 
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Figure 1.1. Structures of antibiotics from each class are shown.  
 
Although antibiotics have helped decrease the number of deaths in the world, 
antibacterial resistance has emerged due to overuse. According to the U.S. Center for 
Disease Control & Prevention (CDC), antibacterial resistance causes 23,000 deaths per 
year in the U.S. Along with C. difficile and N. gonorrhoeae, ESKAPE (E. faecium, S. 
aureus, K. psneumoniae, A. baumannii, P. aueruginosa, and E. coli) defines the list of 
antibacterial resistance threats.18-19 The antibiotic targets and resistance mechanisms 
are summarized in Figure 1.2.7-8, 14 The mechanism of action for antibiotics generally 
relies on interacting with a given target and altering its structure and/or function. The 
locations are indicated in Figure 1.2. Organisms have found ways to avoid these 
mechanisms, leading to drug resistance. The resistance mechanisms fall into four 
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general categories: efflux, target modification, drug modification by enzymes, and target 
enzyme inactivation.20-22 It can be noted that the mode of action is usually through one 
type of mechanism, while the resistance happens in more than one type of mechanism 
(Figure 1.2). Understanding these resistance mechanisms is critical for the development 
of new classes of drugs. 
 
 
Figure 1.2. The locations of antibiotic targets and the resistance mechanisms are 
summarized, along with examples of drugs in each category.7-8, 14-15 Modes of action are 
labeled on the left side of the figure. Most of the known antibiotics have developed 
resistance through four main mechanisms, which are listed on the right. 
 
 
Aminoglycosides are widely used drugs that have been subject to multiple routes of 
resistance.13-14, 17 Aminoglycosides contain 2-deoxystreptamine (2-DOS) moieties that 
are highly charged (Figure 1.3), and bind to many RNAs through electrostatic 
interactions.9, 14 The 2-DOS moiety is proposed to stabilize a specific conformational 
state of A1492 and A1493 in the 30S subunit that results in miscoding.23 The amino 
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groups are positively charged under physiological conditions, which make the 
aminoglycosides overall highly charged. Aminoglycosides face resistance mainly due to 
modification on their amino or hydroxyl groups.10, 17, 24 For that reason, they have been 
modified by addition of different moieties, simplification of their structures, or the 
formation of hybrid structures, in helping protect them from further modification by 
resistance enzymes and/or to improve their binding to the RNA target.25-26 
 
 
Figure 1.3. Structures of two representative aminoglycosides that contain the 2-DOS 
moiety are shown. The 2-DOS moiety highlighted in red, which is an important scaffold 
for RNA binding, is highly conserved among this class of antibiotics. 
 
 
 
Although drug resistance is increasing, approval and discovery of new compounds is 
decreasing.27-28 The reason for this decline in drug discovery is due to high costs and low 
profitability because of inherent resistance of naturally derived compounds.29 To 
overcome this problem, new approaches are needed such as discovery of new targets 
or development of new classes of compounds to target bacteria.3 In this thesis work, my 
goal was to catch two birds with one stone by studying a new target, helix 69 (H69) of 
23S rRNA of the bacterial ribosome that is known to play important functional roles,30-33 
and by using phage display to identify a new class of peptide molecules to target H69.  
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1.2. Helix 69 of the 50S ribosome subunit  
1.2.1. Structure of helix 69  
Helix 69 (H69) is a 19-nucleotide (nt) motif residing in 23S ribosomal RNA (rRNA) of 
the 50S subunit in bacterial ribosomes.33 The sequence of H69 is 5′-
GGCCGΨAACm3ΨAΨAACGGUC-3′, in which A, G, C, U, Ψ, and m3Ψ are adenosine, 
guanosine, cytidine, uridine, pseudouridine, and 3-methylpseudouridine, respectively 
(Figure 1.4).34-35 Pseudouridinylation is the most commonly occurring modification of the 
nucleoside, in which the uracil base is detached from the ribose by an enzyme called 
RluD, rotated by 120°, then reattached to the sugar.36-39 The glycosidic linkage becomes 
a C-C bond, and through the isomerization reaction, an extra imino group becomes 
available for hydrogen bonding.40 Three Ψs are observed in H69, with methylation at 
Ψ1915.33-34, 41  
 
 
 
Figure 1.4. The structures of the nucleosides found in H69 are shown. 
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The sequence and structure of H69 are conserved throughout phylogeny, and the H69 
motif is also observed in humans (Figure 1.5).34, 41-42 In human H69, five Ψs are 
observed, and unlike E. coli, methylation does not occur at Ψ3731.34 Previous NMR 
studies showed that the Ψs stabilize RNA due to increased base stacking,43-44 while the 
individual nucleoside modification destabilizes the overall H69 structure.45 The 
secondary structure of H69 is reported to be a hairpin loop, in which residues G1906-
Ψ1911 form hydrogen bonds to residues A1919-C1924 to stabilize the hairpin structure, 
and A1912-A1918 form the loop.46 In human H69, there is a G at position 3734, whereas 
E. coli H69 contains an A at the corresponding 1918 position.47 There is a G1907-U1923 
wobble base pair in the stem.46 There is also a reverse-Hoogsteen base pair at A1912-
Ψ1917 in the wild-type (WT) and ΨΨΨ variants, which was suggested to stabilize H69 
structure.48-49 
 
 
Figure 1.5. The sequences and secondary structures of H69 synthetic variants are 
shown. Variations include: a) E. coli WT H69, b) E. coli modified H69 ΨΨΨ, c) E. coli 
unmodified H69 UUU, and d) human H69. 
 
1.2.2. Post-transcriptional modifications in the ribosome  
Post-transcriptional modifications, such as Ψ, observed in rRNA, are proposed to play 
roles in regulation of the functions of rRNA by altering binding interactions or ligand 
recognition.48, 50-51 Modifications can occur by breaking the glycosidic bond or altering the 
bases in either a simple or complex manner (Figure 1.6). More specifically, there are 
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four major types of modifications: isomerizations, methylations of the base, methylations 
of the sugar (2’-OH), and multiple modifications.48, 52  
 
 
Figure 1.6. Nucleoside structures and examples of the four major types of 
modifications: isomerization, methylation of the base, methylation of the sugar, and 
multiple modifications are shown in pars a-d, respectively.  
 
 
To date, 36 modified nucleosides have been reported to occur in E. coli ribosomes in 
the PTC and A site, regions essential for translation.50, 52-53 This correlation implies a 
functional significance of the modified nucleosides for translation. Modifications of the 
rRNA can result in altered interactions with other RNAs, proteins, or cofactors, likely fine-
tuning the ribosome structure and function during translation.32, 54 Modifications of the 
rRNA will affect direct contacts, stacking, or base-pairing interactions, thus stabilizing or 
sometimes destabilizing the complex.48, 50 Therefore, rRNA modifications are factors that 
cannot be overlooked in antibiotic development studies. 
1.2.3. Function of helix 69  
Helix 69 comprises the intersubunit bridge B2a, where the 50S and 30S subunits 
interact to form the complete 70S ribosome (Figure 1.7).46, 55-56 The interaction is mainly 
between those two subunits with helix 44 (h44) of the 30S subunit, in which A1913 of 
H69 moves into a pocket formed by h44 and contacts the ribose of the A-site tRNA.57-58 
Residue A1912 also interacts with C1407 and G1494 of h44, and A1919 interacts with 
U1495.46, 49, 59 The loop region of H69 interacts with tRNA, which is important for tRNA 
selection and can lead to miscoding when mutations take place.59-60 Crystal structures 
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have also shown that residues in the stem region, namely G1921 and G1922, interact 
with the D stem of the P-site tRNA.46, 58 It was also reported that H69 interacts with 
release factors (RF1 and RF2) at C1914 and the ribosome recycling factor (RRF) at 
Ψ1915 and A1916, which indicates the multiple roles of H69 in translation.61-63 
Ribosomes lacking Ψ have been reported to cause slower growth rates of E. coli and 
have reduced subunit association in vitro, with a corresponding loss in fidelity and 
translation termination.30, 64 
 
Figure 1.7. The location of H69 in the ribosome is shown. The figure is a cartoon 
representation of the PDB structure 4V50 with h44 and H69 of bridge B2a in space-
filling mode.65 
 
1.2.4. The conformational change of helix 69  
As mentioned in the previous section, H69 is located in the B2a intersubunit bridge.46, 
55-56, 63 Helix 69 undergoes a conformational change involving A1913 in the loop as it 
makes direct contacts with A1493 in h44 during ribosome assembly.32 Residue A1493 of 
h44 plays important roles in decoding; thus, certain modifications or mutations in the 
interacting H69 loop region will affect translation. H69 can be induced to undergo 
conformational changes with differing solution conditions, such as altered pH or Mg2+ 
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concentrations.66-67 At low pH values (~5.5) and low Mg2+ concentrations (0 to 5 mM), 
residue A1913 of H69 displays a stacked-in conformation. In contrast at higher pH 
values (~7.5) and increased Mg2+ concentrations (6 to 10 mM), the same nucleotide flips 
out and becomes more exposed to solvent.67 These conformations are referred to as 
“closed” and “open”, respectively (Figure 1.8). Higher Mg2+ concentrations induce more 
changes with modified H69 (ΨΨΨ), when compared to the corresponding unmodified 
H69 (UUU).67 These changes were observed in solution and in X-ray structures with full 
ribosomes as well as the model systems.66-68 Based on these structural changes, which 
were observed in crystal structures of 50S (closed)55 and 70S (open)69 ribosomes, pH- or 
salt-dependent studies were performed on H69 in this study. 
 
 
 
Figure 1.8. Two different conformational states of H69 are shown. The H69 domain 
from X-ray crystal structure of either 70S (open)69 or 50S (closed)55 ribosomes is 
shown. 
 
1.3. Peptides as drugs  
1.3.1. General information on peptide drugs  
Peptides have been used as drugs for more than 70 years,70 and have been promoted 
in the field since Merrifield developed solid-phase peptide synthesis.71 Traditional 
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peptides such as oxytocin, insulin, and cyclosporine are still commonly used. There are 
also newer peptide drugs developed commercially in use.70, 72 Lantus developed by 
Sanofi-Aventis, also known as insulin glargine (an insulin analogue that helps control 
sugar level of diabetic patients), was one of the top ten biological drugs sold in 2013.73 
Its structure is very similar to insulin, except that the asparagine residue at position 21 
was replaced with glycine, and two arginines were added to the C-terminus. The 
arginines raise the pI of the peptide, causing it to aggregate under physiological 
conditions such that release into the bloodstream is slowed down.73-74  
Peptides are desirable drug candidates because of low toxicity, high diversity of 
sequences, lower immunogenicity, and high specificity for their targets.70, 75 If the 
shortcomings of peptides, such as poor membrane permeability or poor metabolic 
stability could be overcome, peptides would be ideal drug candidates.70, 75 There are 
many ongoing studies to improve peptide-based ligands as potential drugs (Figure 
1.9).75-76  
 
Figure 1.9. A generic peptide structure along with some possible modifications is 
depicted.  
 
One of the methods for improving peptide function is conjugating them to a moiety that 
has desired activity, such as increasing cell permeability or potency.77-79 In general, 
peptides tend to have poor cellular delivery, which can be improved by attaching a 
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hydrophobic chain, lipids, or sugar moieties. Similarly, conjugating a peptide to a potent 
drug molecule can lead to synergistic effects.80  
A weakness of peptides as drugs is their short half-life due to degradation by 
peptidases.81-83 However, several methods utilize D-amino acids, non-natural amino 
acids, peptoids, or cyclization to decrease recognition and breakdown by peptidases, 
thus improving drug stability.81, 84-85 Synthetic peptides have other advantages as drug 
leads because they can be improved in relatively easy fashion, through methods such as 
peptide scanning of alanine, proline, or D-amino acids.83, 86-87 Through amino acid scans, 
important residues for the configuration and activity of a peptide can also be 
determined.83 Peptoids employ N-substituted glycine to alter the peptide backbone and 
make it resistant to peptidases.88 Furthermore, various functional groups can be 
attached to the amino group, allowing development of large combinatorial libraries.89  
Combinatorial libraries have been widely used, not only to screen for new drugs 
against known targets, but also for known drugs against new targets.90 In addition, 
structure-activity relationship (SAR) studies that employ molecular dynamics simulations 
to predict or optimize new drugs have been increasing in the medicinal chemistry field, 
particularly due to advances in computational chemistry.76-77, 91 For such applications, 
peptides are typically easier to synthesize than complex natural products. Nowadays, 
development of native chemical ligation or click chemistry has also allowed for larger 
peptides to be generated and tested for activity.92-93  
1.3.2. Antimicrobial peptides  
In nature, antimicrobial peptides (AMPs) are produced in plants, fungi, and animals, so 
that the organisms can protect themselves from microorganisms. The first AMP, 
defensin, was discovered through extraction from soil by Dubos in the 1930s.94 Some 
examples of antimicrobial peptides are listed in Table 1.2. Most AMPs target the cell 
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membrane, strongly relying on their highly charged structures.95-96 Some of the 
commonly used AMPs target the ribosome as well.84 
 
Table 1.2. Antimicrobial peptides and their targets  
name description mode of action 
defensin94 
Cys-rich cationic antimicrobial 
peptide (AMP) forming β sheets  
forms pores in membranes, 
inducing ion loss 
vancomycin97 tricyclic branched glycopeptide inhibition of cell wall synthesis  
capreomycin98 cationic cyclic peptide  
inhibition of translocation by 
interacting with h44 and H69 of 
70S ribosomes 
edeine6 
pentapeptide with non-natural 
amino acids and a polyamine 
translation-initiation inhibition by 
targeting the 30S subunit 
thiostrepton99-100 
macrocyclic thiopeptide with 
multiple post-translational 
modifications 
translation inhibition by blocking 
IF2 and EF-G 
daptomycin101 
13-mer cyclic peptide with a 
decanoyl group attached 
disrupts cell membranes by 
forming aggregation that makes 
pores, leading to ion loss 
 
In Figure 1.10, the structures of several AMPs are shown. Vancomycin (Figure 1.10a) 
is a glycosylated cyclic peptide that disrupts cell wall synthesis. Unlike the well-known 
penicillin that forms a peptidoglycan intermediate with a β-lactam, vancomycin blocks 
transpeptidation and transglycosylation by forming five hydrogen bonds with the 
peptidoglycan, a property that is enhanced by the concave structure of the drug.102  
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Figure 1.10. The chemical structures of several antimicrobial peptides  
Daptomycin is a membrane-active lipopeptide that was originally extracted from S. 
roseosporus and is now produced synthetically.96 Daptomycin has a cyclic peptide 
structure with D-amino acids and a hydrophobic decaonyl chain.103 The decanoyl chain 
attaches the peptide to the membrane. As can be seen in Figure 1.10b, the peptide 
structure contains multiple carboxylic acid groups, making it negatively charged.103 The 
anionic peptide attracts Ca2+ ions, and after the decanoyl chain attaches itself to the 
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membrane, a micelle-like structure of daptomycin forms a pore and disrupts the 
membrane.96  
Edeine (Figure 1.10c) targets the 30S subunit and inhibits translation initiation by 
blocking fMet-tRNA binding at the P site (peptidyl site).6, 104 Edeine possesses non-
natural amino acids such as β-serine, 2,3-diaminopropanoic acid (DAPA), 2,6-diamino-7-
hydroxyazelaic acid (DAHAA), β-tyrosine, and spermidine, which make this molecule 
highly positive. The cationic nature of the peptide facilitates its interactions with 
negatively charged rRNA.  
The ribosome is a common target for AMPs. Capreomycin (Figure 1.11) and viomycin 
inhibit translocation by interacting with h44 and H69 of the 70S ribosome.98, 105 
Capreomycin is a cyclic peptide containing a decanoyl chain and amino groups that 
provide cationic properties. The constrained ring structure allows capreomycin to 
position itself in the binding pocket that includes A1493 of h44 and A1913 and C1914 of 
H69.106 Another peptide drug oncocin targets the 70S ribosome by blocking access to 
the A and P sites, PTC, and the peptide exit tunnel of the 50S subunit.107 The AMPs are 
typically rich in cationic residues and interact with the ribosome through H-bonding, 
charge-charge, or π-interactions, which can be weakened by modification.105, 107  
Figure 1.11. Antibacterial peptide capreomycin IB, a drug that targets the ribosome, 
interacts with A1492, A1493, and G1491 of h44, and A1913 and C1914 of H69 and 
acts by disrupting the interface between h44 and H69 (PDB ID 3KNO).106 
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1.4. Background on techniques used in this study  
1.4.1. Phage display  
Phage display was developed by George P. Smith in the early 90s.108-109 Phage 
display is a biological tool that uses phage particles to express peptides on their 
surfaces, which can be used to select peptides that have binding affinity to a target of 
interest.109 In this study, the Ph.D.-7 library from New England Biolabs was used. This is 
a linear heptapeptide library of 207 size complexity (diversity). By integrating DNA 
sequences encoding the peptide that will be expressed on the pIII coat protein into the 
M13KE vector, a randomized phage library is obtained. The pIII coat protein is a minor 
protein among those proteins that comprise the phage particle, which allows it to attach 
and infect the host. The pIII coat protein is composed of five copies of proteins, to which 
the randomized peptides are attached through their N-termini (Figure 1.12). Therefore, 
five copies of the peptides are expressed on the phage surface. The diversity in peptide 
sequences is 20n (where n is the number of amino acids in the peptide), and therefore a 
pool of peptide ligands can be expressed and selected for affinity to a given target.109-110 
The foreign peptide or protein can also be engineered to be attached to other coat 
proteins or antibodies or manipulating the number of peptides displayed.111-114 
 
Figure 1.12. A generalized structure of M13 phage used for phage display 
The DNA of the phage encode a lac operon to allow for blue/white screening. 
Therefore, after each round of selection, the phage can be titered and quantified. Phage 
titering is an important technique for molecular biology, and in this case, for the phage 
display method. Following a selection experiment, it is of interest to determine the phage 
population. In order to quantify this process, the number of phage plaques were counted 
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after each step of biopanning. Ideally the number of plaques should be about 50 to 500 
on each agar plate. Because the phage are viruses, they can use a host such as E. coli 
to reproduce. For the commercial Ph.D.-7 libraries, randomized peptide sequences are 
inserted into the vector M13KE to be expressed on the N-terminus of the pIII coat 
protein.115-117 The peptide sequences are inserted in between restriction enzyme sites 
EagI and KpnI, with Gly-Gly-Gly-Ser in between the peptide sequence and the pIII 
surface.  A yield can be obtained for the phage selection by comparing the number of 
input and output phage. Following this step, the phage are amplified using E. coli as a 
host. This step provides enough phage to carry out the biopanning step again. In the 
case of the Ph.D.-7 library, the initial selection step starts with 207 clones, which contain 
1.3 million different sequences with 70 copies each. Thus, carrying out 3 to 4 rounds of 
selection and getting hundreds of sequences are necessary to identify consensus motifs. 
 
Figure 1.13. A general scheme of phage display (biopanning procedure) is shown. To 
a random phage library, biotinylated target is added. Following incubation, 
streptavidinlyated magnetic beads are added, and after several washing steps, the 
bound phage is isolated. Specific/nonspecific elution allows disruption of the complex 
of phage/target on streptavidinlyated magnetic beads and bound phage are obtained. 
The bound phage are amplified using E. coli as the host. After several repeated rounds 
of biopanning, the DNA encoding the peptides binding to the target can be identified.  
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The general protocol (referred to as biopanning) for the phage display experiment is 
summarized in Figure 1.13. The library is incubated with a target that is attached to a 
surface such as a magnetic bead using streptavidin-biotin chemistry. The phage having 
affinity to the target can be isolated after the washing steps. In nonspecific elution, 
noncovalent interactions of the target and phage are disrupted by adding an acidic buffer 
and the bound phage are released from the target. Specific elution involves incubation 
with a non-biotinylated target that competes for binding to the selected phage with the 
immobilized target. Addition of either the target or a variant of the target for counter 
selection allows for selective elution of phage with affinity for a given molecule, rather 
than eluting all bound phage that may include some nonspecific binders.  
In previous studies in our lab, phage display has been performed under physiological 
buffer systems against h31, h44, or H69.118-120 In this thesis work, phage display against 
H69 was done under several different buffer conditions, and mainly focused on phage 
display at low pH (pH 5.5). A previous study employed phage display at low pH to select 
peptides targeting amylases.121 The low pH was shown to increase binding of phage to 
the target; however, overall phage survival was lower and more polar sequences were 
selected.121 In this study, selection was carried out with nonspecific elution to ensure 
higher yields of bound phage. To our knowledge, there have not been phage display 
studies done at low pH against RNA.  
One challenge in this study, which will be discussed in a later chapter, is that our RNA 
target is an essential component of the bacterial ribosome. Because we use E. coli as 
the host for amplification, any peptides that display antibiotic activity through rRNA (H69) 
targeting will be lethal, and therefore will not be amplified. Therefore, the possibility of 
selecting a peptide that is fatal for the host is low. Also, some phage are known to be 
fast growers over other phage, which can decrease the chance of slow-growing phage to 
be potent. However, considering that the small peptides selected through phage display 
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are likely to have only moderate binding affinities, the selected peptides will be 
considered only as starting peptides (i.e., “parents”) that can further be modified through 
amino acid scanning or structure-activity relationship (SAR) studies. 
1.4.2. Solid-phase peptide synthesis  
Solid-phase peptide synthesis was first developed by Bruce Merrifield in 1963, 
proceeding through anchoring the C-terminus of an amino acid onto a solid support.71 
The solid supports are polymer-based resins, and the functional groups vary so that the 
C-terminus of the cleaved peptide can be a carboxylic acid or an amide.122 Depending 
on the size or use of the desired peptide, one can choose resins with different loading 
levels or swelling properties.  
Usually amino acids with a fluorenylmethyloxycarbonyl (Fmoc) on the N-terminus are 
employed (Figure 1.14), wherein Fmoc is a base-labile protecting group.123-124 The side 
chains are typically protected with acid-labile protecting groups. Having orthogonal 
protecting groups is essential for the sequential addition of selected amino acids.125  
 
Figure 1.14. Structures of reagents commonly used in solid-phase peptide synthesis 
are shown.  
 
Addition of Fmoc-protected amino acids is done with carboxylate-activating coupling 
reagents, such as N,N’-dicyclohexylcarbodiimide (DCC).71 Hydroxy groups are poor 
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leaving groups, so addition of a carbodiimide activates them to increase the 
electrophilicity of the carbonyl group. To the reaction, the coupling agent is added at a 
concentration of 2 equivalents (2 eq.) relative to the amount of resin (i.e., if there is 1 g of 
0.68 mmol/g, 1 eq. is 0.68 mmol), along with 2 eq. of Fmoc-protected amino acids, to 
facilitate the reaction. However, the byproduct of the reaction is urea-based, and in the 
case of DCC coupling, racemization can occur.126 To reduce this problem, phosphonium 
salts such as Castro’s reagent (benzotriazol-1-yloxytrisphosphonium 
hexafluorophosphate, BOP) or O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate (HBTU) were developed as alternative coupling agents.127 
Additives such as 1-hydroxybenzotriazole (HOBt) or 1-hydroxy-7-azabenzotriazole 
(HOAt) may also be added to increase the rate and yield of the reaction.126 In addition, 4 
eq. of diisopropylethylamine (DIPEA) are added to deprotonate the carboxylic acid as 
well as the amino groups of the Fmoc-protected amino acids. Coupling with these 
reagents allows a one-pot synthesis of the peptides to be done. 
Scheme 1.1. Structures of the resins used in this study with a general scheme of solid-
phase peptide synthesis  
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As shown in Scheme 1.1, Fmoc-protected amino acids and coupling reagents are 
added to the resin, followed by deprotection of the Fmoc group using 20% 
piperidine/DMF. This step is generally performed by adding the basic solution once for 5 
min, the solution is then removed, followed by addition of the basic solution for an 
additional 7 min.  
When the peptide coupling steps are completed, the final Fmoc protective group is 
removed, the peptide is cleaved from the solid support, and removal of the acid-labile 
protecting groups are removed by using a "cleavage cocktail".128 The cleavage cocktail 
typically contains trifluoroacetic acid (TFA) with various scavengers, such as 
triisopropylsilane (TIPS), thioanisole, phenol, and water. When the protecting groups are 
cleaved by TFA, radicals can be formed, which can react with the peptide products. 
Therefore, scavengers are added to increase the purity of the products by capturing the 
protecting groups. The concentration of each component varies depending on the 
protecting group or resin in use.  
Following incubation with the cleavage cocktail, the slurry is filtered into cold diethyl 
ether to precipitate the peptide, and after several washes, a crude peptide is obtained. 
For short peptides, or those with high solubility in ether, precipitation may be inefficient, 
wherein extraction with organic solvents may be needed. For further purification, high 
performance liquid chromatography (HPLC) is typically used. In cases in which the 
peptide is insoluble in water due to high hydrophobicity, HPLC cannot be used for 
purification. In such cases, extraction in organic solvents followed by column 
chromatography or prep-TLC (thin layer chromatography) can be used.129  
Solid-phase peptide synthesis has been widely used because of its advantages 
compared to conventional solution-phase organic synthesis.124-125 In general, the 
procedures are relatively simple and the products can be obtained with high yields and 
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purity because of the washing and filtering steps, which can also be automated. Unlike 
natural products that require multi-step syntheses in controlled systems, peptides are 
easier to synthesize and modify. Therefore, with starting parent sequences or motifs, the 
development of a potent therapeutic by rational design has been emerging.130-131 
Development of peptoids, cyclic peptides, and multimeric peptides has expanded the 
range of peptide-related drugs.89, 130, 132,133 Pharmaceutical research can now leverage 
these tools in discovery of peptide-related drugs.  
1.4.3. Fluorescent intercalator displacement (FID) assay  
Fluorophores (or dyes) absorb specific wavelengths of light (excitation), followed by 
emission as they relax.134 Due to the fact that one can selectively monitor a molecule 
with fluorescence spectroscopy, many binding studies rely on fluorescence by attaching 
a dye to the molecule of interest (i.e., the target).67, 135-136 However, because the dye tag 
can alter binding affinities of the target, label-free methods are preferred if possible. Most 
fluorophores used in fluorescence studies have planar structures with multiple aromatic 
rings conjugated with high resonance, which not only delocalizes the electrons, but allow 
for favorable interactions with DNA or RNA. A fluorescent intercalator displacement 
(FID) method is a label-free experiment involving a dye that fluoresces only when it is 
intercalated or surface bound to the target.137-141 The fluorescence then generally 
decreases if a ligand binds and removes the dye through direct or indirect displacement, 
such as changing the conformation of the target.140-141 The FID assay has several 
advantages as a screening assay. First, utilization of a sensitive dye requires only a low 
amount of material (for both the dye and target). Second, this assay is simple, both in 
terms of sample preparation and data collection, compared to methods such as surface 
plasmon resonance (SPR) or electrospray ionization mass spectrometry (ESI-MS) (see 
Sections 1.4.4 and 1.4.5). Third, physiological buffers are typically suitable for use in 
these experiments, which is not possible with ESI-MS or nuclear magnetic resonance 
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(NMR). However, there are some weaknesses with the method. One weakness is that 
only a change in signal is detected, indicating a binding event, but not the binding site. 
Another shortcoming is that because the dye is displaced by a ligand under equilibrium 
conditions, there is competition between the ligand and dye for the target, which makes 
the FID assay a qualitative rather than a quantitative method. In addition, a lack of 
fluorescence change does not necessarily mean that a binding event did not occur. 
Despite the shortcomings noted, this method is still relatively fast and can be used in a 
96- or 386-well plate format, making it a good tool for high throughput screening 
(HTS).138 
 
Figure 1.15. The general scheme for the FID assay is shown. To the target (non-
fluorescent), a dye is added that fluoresces when bound. Addition of a molecule (non-
fluorescent ligand) that can remove the dye by direct displacement or by a change in 
target conformation leads to decreased fluorescence. 
 
1.4.4. Electrospray ionization mass spectrometry (ESI-MS)  
Electrospray ionization mass spectrometry (ESI-MS) is a soft ionization technique that 
can be used to determine the mass of a molecule or a target-ligand complex.142 The 
method has many strengths. ESI-MS is very sensitive, therefore only requires a small 
amount of sample (pmol to low nmol range), which does not need to be labeled or 
tagged. In addition, the apparent dissociation constant, or Kd, and stoichiometry of the 
complex can be obtained. The components of a mass spectrometer typically include an 
ionizer, analyzer, and detector (Figure 1.16). The electrospray process nebulizes the 
liquid to form highly charged droplets, then a heated nitrogen gas helps to evaporate the 
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solvent and reduce the droplet size.143-144 The charges move to the surface to minimize 
Coulombic repulsion and form ions, and as the solvent evaporates the droplet sizes get 
smaller. When the Coulombic repulsion exceeds the surface tension (Rayleigh limit), the 
droplets explode to make smaller droplets.142 This step leads to fragmentation of the 
droplet. Compared to laser-assisted methods such as MALDI-TOF, ESI-MS is a soft 
ionization method. The droplets travel through the analyzer, which filters the ions 
according to their mass-to-charge ratio (m/z). Those that reach the detector are recorded. 
The soft ionization of ESI-MS allows noncovalent interactions of complexes to be 
monitored.142, 145 Therefore, this method is a powerful tool for examining binding of 
various ligands to biomolecules such as RNA.146-147 ESI-MS also provides the 
stoichiometry of the complexes, which is an advantage when trying to understand ligand 
binding modes.  
 
Figure 1.16. A general depiction of ESI-MS is given. In RNA-peptide binding studies, 
the negative ion mode is used. The negative charges on the RNA are neutralized by 
NH4
+, and AcO- ions are located on the surface of the droplets, which does not change 
the overall charge of the molecule. As the negatively charged droplets travel through 
the source region or mass analyzer, they break into smaller droplets due to Coulombic 
repulsion, and reach the detector as single ions. 
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As with the other methods mentioned, there are limitations to the ESI-MS method. The 
ideal salt concentration of the buffer used in ESI-MS experiments is usually 10-20 mM, 
which is much lower than physiological conditions.148 Furthermore, Na+ or K+ typically 
need to be eliminated, because adducts with these salts can give poor fragmentation 
and high noise levels. Studies have shown that an increase in the salt concentration also 
alters the charge state distribution, and can disrupt hydrophobic interactions between 
molecules.149-150 Volatile solvents such as acetonitrile or isopropanol are typically 
employed in ESI-MS. Although these solvents are not physiological buffers, they can 
help the droplet formation by decreasing the surface tension.145 The ionization 
efficiencies of the free target and complex can be different.146 Therefore, it is necessary 
to use complementary methods to verify the binding constants obtained from ESI-MS. 
1.4.5. Surface plasmon resonance (SPR)  
1.4.5.1. The principle of SPR on Biacore 
As mentioned in previous sections, binding affinities or dissociation constants can be 
measured using a variety of methods, each with advantages and limitations. Surface 
plasmon resonance (SPR) (e.g., Biacore) is another powerful method to study 
biomolecular interactions.151 A surface plasmon is an electromagnetic wave that occurs 
when a beam of incident light is shone onto a prism with a thin gold surface. The light 
generates an evanescent wave with refraction occurring along with reflection (Figure 
1.17a). At the angle where there is total reflection and no refraction, the angle is called 
the total internal reflection (TIR). At an angle that is larger than TIR, surface plasmon 
resonance (SPR) takes place, and the energy of the photon converted into a plasmon 
creates a dark band in the reflected light (Figure 1.17b). The dark band shifts when 
there is a change in the refractive index (i.e., change on the surface mass). The TIR 
angle is related to the mass of the surface, and a mass change results in a shift of the 
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TIR angle. Therefore, by monitoring the change of mass on a surface with an 
immobilized target, binding of a ligand can be quantified (Figure 1.17c and 1.17d).152-153  
 
Figure 1.17. A description of surface plasmon resonance is given. a) The light shone 
generates an evanescent wave, with refraction occurring along with reflection. The 
angle where there is total reflection and no refraction is called the total internal 
reflection (TIR). b) At an angle that is larger than TIR, surface plasmon resonance 
(SPR) takes place, and the energy of the photon converted into a plasmon creates a 
dark band in the reflected light. c) The TIR angle is related to the mass of the surface, 
and a mass change results in a shift of the TIR angle. d) By monitoring the change of 
the TIR angle, and thus the mass, on a surface with an immobilized target, binding of a 
ligand can be quantified. 
 
The SPR method also has several strengths and weaknesses. SPR requires only 
small amounts of material (pmol to nmol) compared to NMR spectroscopy. By flowing 
through ligands (called “analytes” in SPR)152 that have affinity to the immobilized target 
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(often called “ligand” in SPR), real-time binding can be monitored. This method provides 
information of kinetics of the interaction along with the apparent dissociation constant. In 
this case, a wide range of buffers can be used, which allows studies to be carried out 
under differing conditions including physiological salt concentrations and pH values. 
Thus, the ability to obtain kinetic information under high salt conditions makes this 
method advantageous compared to ESI-MS or NMR spectroscopy.  
Despite the advantages of SPR, the Biacore system requires use of an expensive 
sensor chip. In order to immobilize a molecule onto the sensor chip, a tag such as biotin 
needs to be attached to the target. Also, the signal detected is correlated with the 
change in mass of the surface; therefore, when a lighter molecule is immobilized as a 
target, the change of signal when a larger ligand binds is detected more clearly.154 For 
studies of RNA-peptide interactions, the RNA is usually immobilized to the surface due 
to its high cost. To increase the response to smaller ligands, RNA is typically 
immobilized in high density.155 As a result, mass transport can also be a problem, which 
is caused when the binding rate of the ligand to the target is faster than diffusion.156 
Smaller amounts of the target need to be immobilized in order to minimize mass 
transport effects. In RNA-peptide binding studies, this can cause a conflict with the need 
for higher loading levels of RNA. Therefore, optimization is required to find the maximal 
amount of target to immobilize in order to reduce mass transport problems. 
1.4.5.2. Bio-Layer Interferometry (BLItz)  
SPR is an ideal method for monitoring biomolecule interactions; however, the Biacore 
system is not cost or time efficient compared to methods such as FID. Recently, 
companies have been developing more cost-effective instruments that operate with 
similar methods.157-158 For example, bio-layer interferometry (BLItz) is one of those 
techniques.157, 159-161 Though the actual mechanism of the technology is proprietary, the 
method is based on SPR using white incident light. The light is shone onto the biosensor 
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with a target immobilized, and when there is a change on the surface, the signal 
obtained from the biosensor changes. However, a detailed mechanism of the instrument 
is not provided. 
 
Figure 1.18. A schematic diagram of BLItz is shown. a) The sensor components are 
given. To an optical sensor with streptavidin, a biotinylated target can be immobilized. 
b) For association, the sensor with the target immobilized is dipped into a buffer 
containing the ligand, and the association is observed. c) The sensor from b) is dipped 
into buffer, and the dissociation is measured.162 
 
There are two differences between this method and Biacore SPR. One is that the 
sensor is on a tip that can be easily removed and immobilized with target. The other 
difference is the association/dissociation method.157, 162 In Biacore, there is a flow of the 
buffer containing ligand to allow for association and dissociation.162 In BLItz, the tip 
sensor is place into a solution containing the ligand for the association step (with 
agitation of the sample), and then the tip sensor is placed into another buffer for the 
dissociation step (Figure 1.18).161 In SPR, the concentration of the ligand solution or 
buffer stays constant but is flowing over the target. In BLItz the concentration of the 
ligand solution or buffer may decrease or increase during the association or dissociation 
step, which may affect the true binding. Therefore, to minimize concentration effects, 
fresh samples are required, and the sample is agitated takes place while monitoring 
association and dissociation. 
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1.4.6. Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectroscopy is a useful technique for observing RNA structure in solution. Each 
nucleus of a molecule has an electric charge and spin, which gives a unique chemical 
shift when an external magnetic field applied. Depending on the chemical environment of 
the atom, which can vary with neighboring functional groups or interactions, the chemical 
shifts or coupling patterns are affected. In this study, 2D proton homonuclear correlation 
spectroscopy (ge-2D COSY) was used to monitor the resonance from the crosspeaks 
between the H5 and H6 of pyrimidines.163 This method detects proton coupling; therfore, 
a change in the chemical environment upon ligand binding can be monitored. Compared 
to other 2D NMR experiments, COSY experiments require less sample (3 OD, 15 nmol). 
Therefore, for binding experiments with expensive targets such as the RNA, COSY was 
selected as the best NMR method. 
There are strengths and limitations to NMR spectroscopy. When there is a change in 
the chemical shift, this typically indicates a change in the local chemical environment 
such as an altered conformational state of the molecule or interaction with a ligand. In 
this thesis work, NMR spectroscopy was used for RNA-peptide binding studies. This 
method can give information about the binding site (i.e., which nucleotides interact with 
the ligand), which is not obtained directly from SPR or fluorescence studies. However, 
NMR requires large amounts of highly pure sample. Synthetic RNA, which is typically 
necessary for modified samples, is expensive; therefore, this method is not as cost-
efficient as ESI-MS or fluorescence studies. Because of the various limitations, it is best 
to have more than one method to obtain the apparent dissociation constant (Kd) for a 
target-ligand complex. In Table 1.3, the strengths and limitations of the approaches used 
for binding studies in this thesis work are summarized.  
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Table 1.3. A comparison of various biophysical methods for determining RNA-ligand 
interactions.  
 
Method Advantages Disadvantages 
FID 
assay 
 pmoles of sample required 
(both dye and target) 
 simple to perform 
 label-free 
 physiological buffer can be 
used 
 cannot obtain apparent K
d
 
directly 
 cannot determine stoichiometry 
 changes in fluorescence are 
difficult to predict or interpret 
ESI-MS 
 pmoles of sample required 
 apparent K
d
 values obtained 
 stoichiometry obtained 
 label-free 
 cannot use physiological buffers 
 extensive sample purification 
required 
SPR 
 pmoles of sample required 
 physiological buffer can be 
used 
 apparent K
d
 values obtained 
 kinetic information obtained 
 need to label the target 
 typically the ligand needs to be 
larger than the immobilized 
target 
 expensive instrumentation and 
consumables 
BLItz 
 more cost and time effective 
compared to SPR 
 pmoles of sample required 
 physiological buffers can be 
used 
 apparent K
d
 values can be 
obtained 
 need to label the target 
 typically the ligand needs to be 
larger than the immobilized 
target 
 expensive consumables 
NMR 
 label-free 
 binding site of a ligand can be 
determined 
 large amount of sample required 
 limitations on buffers 
 challenging to obtain apparent 
K
d
 values 
 challenging to determine 
stoichiometry 
 
1.5. Overall project objective  
 Due to the rise of antibiotic resistance, there is a need for discovery of new targets 
and development of novel drugs. In our laboratory, we are interested in helix 69 (H69), 
an rRNA motif located in the B2a intersubunit bridge of the bacterial ribosome.164 Helix 
69 interacts with helix 44 (h44), A-tRNA, P-tRNA, RF, and RRF, and forms an 
intersubunit bridge B2a with h44, which makes it an interesting target.30-32, 48, 165 Helix 69 
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also has post-transcriptionally modified nucleosides, pseudouridine (Ψ) and methylated 
pseudouridine (m3Ψ).48 Pseudouridine increases the stability of the helix by increasing 
base stacking, and is conserved across phylogeny.47-48, 166 Helix 69 shows different 
conformations in 50S subunits and 70S ribosomes, which can be altered by changing 
buffer conditions or temperature of the system.66-67 The goal of this project was to select 
a peptide ligand for binding to modified H69 in the stacked-in conformation. If we are 
able to find a peptide ligand that can bind to H69, this ligand may be able to disrupt H69 
interacting with other factors or rRNAs, which will inhibit translation. Phage display was 
used to screen a peptide library under low pH conditions (pH 5.5) with tRNAPhe as a 
competitor to eliminate nonspecific binding peptides.  
The binding studies were performed on model systems. The various methods used 
were in vitro experiments, which give information on the binding interactions in a 
controlled environment outside of the cell. Although the binding may differ in vivo, the in 
vitro experiments allow observations of the binding interactions at the molecular level. In 
this work, in vitro studies are useful because we can observe binding events at both pH 
5.5 and pH 7.0 conditions for both ΨΨΨ and UUU H69, which is not possible for in vivo 
studies. By utilization of multiple methods, we were able to obtain information on the 
relative affinities and modes of binding, stoichiometries, and interaction sites for the 
peptide ligands. We hope these studies provide information for future studies on peptide-
based antibacterial drugs. 
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CHAPTER 2 – METHODS AND EXPERIMENTAL DESIGN 
2.1. Preparation of the RNA 
Modified H69 ΨΨΨ (5′-GGCCGΨAACΨAΨAACGGUC-3′) was purchased from Thermo 
Fisher Scientific (Waltham, MA) on a 1 μmol scale and unmodified H69 UUU was 
obtained by T7 RNA transcription as described below. Adenosine triphosphate (ATP), 
cytidine triphosphate (CTP), guanosine triphosphate (GTP), uridine triphosphate (UTP), 
acrylamide, bisacrylamide, urea, sodium acetate (NaOAc), triethylammonium acetate 
(TEAA), acetic acid (CH3COOH or AcOH), hydrochloric acid (HCl), ammonium persulfate 
(APS), acetonitrile (MeCN), sodium hydroxide, zinc chloride (ZnCl2), ethanol, Microcon 3 
(centrifugal filter unit YM-3 membrane), and alkaline phosphatase were purchased from 
Sigma-Aldrich (St. Louis, MO). Tris, boric acid, ethylenediaminetetraacetic acid (EDTA), 
dithiothreitol (DTT), spermidine, Triton X-100, ammonium acetate (NH4OAc), and 
tetramethylethyldenediamine (TEMED) were purchased from Fisher Scientific (Hampton, 
NH). XTerra C18 column (10 x 50 mm, 2.5 μm) and Sep-pak SPE columns were 
purchased from Waters (Milford, MA) for a Waters 600 LC with a 717 autosampler 
(Waters, Milford, MA, USA) and UV-detector. 
The H69 UUU was synthesized using T7 in vitro transcription.166-167 To HPLC-purified 
DNA template (5′-GACCGTTATAGTTACGGCCTATAGTGAGTCGTATTA-3′) (10 μg, 0.9 
nmol) and T7 promoter (5′-TAATACGACTCCTATAGG-3′) (4.9 μg, 0.9 nmol) in 1 mL of 
1× transcription buffer (40 mM Tris-HCl, 2 mM spermidine, 0.01% Triton X-100), was 
added 7 mM NTPs, 10 mM DTT, and 100 U of T7 RNA polymerase (Epicenter, Madison, 
WI), followed by incubation at 37 °C for 4 h. The transcribed RNAs were purified on 20% 
denaturing polyacrylamide gels with 19:1 acrylamide/bisacrylamide, 1× TBE buffer (90 
mM Tris, 90 mM boric acid, 1 mM EDTA, pH 8.2) and 7 M urea. The RNA band was 
visualized using UV shadowing, followed by excision and extraction through the crush-
and-soak method. After eluting the RNA, ethanol precipitation using 1/10th volume of 3 M 
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NaOAc was performed to desalt. Desalted RNA was then characterized by using 
MALDI-TOF MS as described below. Negative mode on Ultraflex Extreme TOF/TOF 
from Bruker (Billerica, MA) was used for detection. Three-Hydroxypicolinic acid (HPA) 
was used as the matrix.  
Modified H69 ΨΨΨ was purified by HPLC (XTerra C18) in 25 mM triethylammonium 
acetate (TEAA), pH 6.5, by increasing the MeCN concentration from 6 to 12% over 30 
min at a flow rate of 4 mL/min. The collected sample was dried in vacuo, followed by 
ethanol precipitation. The RNA was characterized by MALDI-TOF MS and 20% PAGE. 
For MALDI-TOF MS, 10 pmol of H69 ΨΨΨ in 1 μL of ddH2O, 1 μL of supersaturated 
matrix and 0.05 μL of 10 mM NH4OAc were mixed and allowed to dry on a 384-well 
metal plate before measurement. Negative ion mode on Ultraflex Extreme TOF/TOF 
from Bruker (Billerica, MA) was used for detection, and 3-hydroxypicolinic acid (HPA, 
Figure 2.1a) was used as the matrix. After HPLC, the RNA purity was also checked by 
running denaturing 20% polyacrylamide gel electrophoresis (PAGE).  
Figure 2.1. Structures of matrices used for MALDI-TOF studies are shown. 
 
Digestion with P1 nuclease followed by HPLC analysis was used to confirm the 
presence of pseudouridine in the H69 ΨΨΨ sample. To 0.1 OD of H69 ΨΨΨ in 86.25 μL 
of ddH2O was added 10 U of P1 nuclease, 2.5 μL of 10 mM ZnCl2, and 1.25 μL of 3 M 
NaOAc. The mixture was incubated at 37 °C for 18 h, followed by centrifugation at 5000 
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rpm for 30 min through a Microcon 3 filter. Then, to 60 μL of the flow-through was added 
5 μL of alkaline phosphatase and 3.6 μL of 1 M Tris-HCl (pH 8), and the mixture was 
incubated at 37 °C for 4 h, followed by centrifugation at 5000 rpm for 30 min through a 
Microcon 3. The flow-through was diluted to 100 μL, followed by separation by HPLC. A 
Discovery C18 column (Supelco C18 4.6 × 250 mm, 5 µm, Sigma-Aldrich, St Louis, MO, 
USA) on a Waters 600 LC with a 717 autosampler (Waters, Milford, MA, USA) and UV-
detector was used for separation of the mixture, with 40 mM NH4OAc and 40% MeCN 
used as the buffer. The column was equilibrated with 40 mM NH4OAc, and the eluents 
were separated with increasing concentration of MeCN from 0 to 12% over 30 min.  
For studies such as ESI-MS and NMR studies that are sensitive to impurities and 
buffer conditions, extensive desalting of the RNA is required. In addition to ethanol 
precipitation, Sep-pak SPE columns were used for desalting. Each desalting process 
was done on 50 nmol or less of RNA. The column was first activated by using 10 mL of 
MeCN, followed by washing the column with 10 mL of ddH2O. After the column was 
washed, the RNA was loaded to the column, followed by washing the RNA with 20 mL of 
ddH2O. After desalting, the RNA was eluted with 30% MeCN in ddH2O. The eluted RNA 
was quantified with UV spectroscopy, and lyophilized before use. The extinction 
coefficients for ΨΨΨ and UUU H69 were 187,000 Lmol-1cm-1 and 189,400 Lmol-1cm-1, 
respectively.45 
2.2. Phage display performed against H69 
2.2.1. Biopanning 
In this study, buffers with differing pHs were used for RNA binding. For higher pH 
conditions, 20 mM HEPES-KOH, pH 7.0, 100 mM KCl, 5 mM MgCl2, 5% glycerol, 0.1 
mg/mL BSA with 0.1% (v/v) Tween-20 (buffer A) was used, and for the lower pH buffer, 
20 mM PBS, pH 5.5, 100 mM KCl, 5% glycerol, 0.1 mg/mL BSA with 0.1% (v/v) Tween-
20 (buffer B) was used. To 200 μL of buffer A or B in 1 mL microcentrifuge tube was 
34 
 
 
added the phage library pre-incubated with M-280 streptavidin-magnetic beads (2  1011 
pfu) and 30 pmol of target (biotinylated UUU, 10 µM, Figure 2.2).  
Figure 2.2. Structure of biotinylated H69 UUU is shown. 
 
The mixture was then incubated at room temperature (RT) for 30 min. After incubation 
with RNA, the beads were washed with 200 μL of the buffer five times. After mixing, the 
beads were held against the sample with a magnet, spun down using a microcentrifuge, 
then the supernatant was carefully decanted into another microcentrifuge tube. Next, 
200 μL of buffer was added, and mixing, centrifugation, and removal of the supernatant 
was repeated five times. For elution of the phage, the beads were placed in 100 μL of 
buffer C (0.2 M glycine-HCl, pH 2.2, 1 mg/mL BSA) for 9 min, followed by neutralization 
with 15 μL of buffer D (1 M Tris-HCl, pH 9.1). Then, 10 μL of the eluate was removed 
and placed in a separate 500 µL microcentrifuge tube for titering, and 100 μL of the 
eluate was kept for the next step. 
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Table 2.1. Dilutions prepared for phage libraries  
 
To 5–10 mL of LB, a single colony from E. coli strain ER2738 (New England Biolabs, 
Ipswich, MA) from a plate was inoculated and incubated at 37 °C with shaking to mid-log 
phase (OD600~0.5, 4–8 h). Then, to a pre-warmed LB/IPTG plate per expected dilution 
was spread at 37 °C until ready for use. The serial dilutions were prepared in the 
following manner (Table 2.1).   
 
Figure 2.3. Schematic figure of the steps performed after biopanning is shown. 
 
When the culture reached mid-log phase, 200 μL of the culture was dispensed into 
microfuge tubes, which held phage dilutions. Then, to carry out infection, 10 μL of each 
phage dilution was added to a tube, vortexed quickly, and incubated at room 
temperature for 1–5 min. The infected cells were vortexed briefly, and the culture was 
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immediately poured onto a pre-warmed LB/IPTG plate. The plates were allowed to cool 
and dry for 5 min, inverted, and incubated overnight at 37 °C. Plaques on plates were 
counted that have approximately 100. To each number, the dilution factor was multiplied 
for that plate to get the phage titer in plaque forming units (pfu) per 10 μL, and the % 
yield of the output/input phage was calculated using Equation 2.1.  
Equation 2.1.  
 % yield = 100  (# of output phage  dilution factor) / # of input phage 
 
 
Figure 2.4. A schematic representation of specific elution is given. A nonbiotinylated 
target is added to the complex of phage/target on streptavidinylated magnetic bead to 
wash off the phage that bind selectively to the biotinylated target. 
 
Phage display was performed under various conditions, including pH 5.5 to favor the 
closed conformation, and at higher Mg2+ concentrations to favor the open conformation. 
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Elution was done with differing competing RNAs, such as the H69 stem region, human 
H69, and tRNAPhe to improve peptide selectivity. The elution was performed non-
specifically and specifically. Non-specific elution was performed with an acidic glycine 
buffer, whereas specific elution was performed by eluting the phage with free target 
(Figure 2.4).  
The conditions for washing and elution are displayed in Table 2.2. The selections were 
separately performed from round 3, and biopanning using M-280 streptavidin-coated 
magnetic beads and H69 with various competitors is shown. The washing buffer is the 
same as the binding buffer (buffer A minus Tween-20) with addition of different 
concentrations of Triton X-100. For the first two rounds, only tRNA was used as a 
competitor and only non-specific elution was performed. For specific elution, after two 
rounds, 3 eq. of free (nonbiotinylated) H69 UUU (90 pmol) were added to the solution 
with biotinylated H69 ΨΨΨ and phage that were washed before addition of the H69 UUU. 
  
Table 2.2. Biopanning conditions for rounds 1-4 (pH 7.0) 
round washing 
H69 
(pmol) 
competitor RNA  
(pmol) 
binding 
time (h) 
elution 
1 
3 times, 0.1% 
Triton-X 
30 90 (tRNA) 2 non-specific 
2 
3 times, 0.3% 
Triton-X 
30 90 (tRNA) 2 non-specific 
3 
10 times, 
0.5% Triton-X 
30 
90 (human H69, H69 
UUU, H69 stem, tRNA) 
1 
non-specific 
and specific 
4 
10 times, 
0.5% Triton-X 
30 
90 (human H69, H69 
UUU, H69 stem, tRNA) 
0.5 
non-specific 
and specific 
 
Biopanning using M-280 streptavidin-coated magnetic beads and H69 at pH 5.5 is 
shown in Table 2.3. The washing buffer is the same as the binding buffer (buffer B 
minus Tween-20) with addition of different concentrations of Triton X-100. 
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Table 2.3. Biopanning conditions for rounds 1-4 (pH 5.5) 
 
2.2.2. Sequencing 
For sequencing, DNA templates were prepared by colony PCR. Using an autoclaved 
tip, random colonies were picked from a plate with ~100 colonies. The tip was then used 
to streak a part of the plate, and dipped in 500 μL of ddH2O. The solution was used as 
the DNA template solution for the colony PCR. In a 200 μL PCR tube, 1 master mix 
along with the primers were added with the PCR reaction components. The Green Go 
Taq master mix (2, Promega, Taq DNA polymerase, pH 8.5, 400 μM dNTPs, 3 mM 
MgCl2) contains DNA polymerase, dNTPs, and buffers needed for the polymerase 
reaction.    
reagent    amount       
DNA template   2 μL 
forward primer   4 μL (5’-GCAAGCTGATAAACCGATACAAT-3’) 
reverse primer   4 μL (5’-CCCTCATAGTTAGCGTAACG-3’) 
Green Go Taq master mix 10 μL        
The colony PCR reaction was performed using the following program. The PCR 
protocol included a cycle for 1 min at 98 °C, 34 cycles for 10 sec at 98 °C (denaturing), 
30 sec at 55 °C (annealing), 30 sec at 72 °C (extending), and 1 cycle for 5 min at 72 °C, 
followed by holding at 4 °C. After the PCR cycles are done, the concentrations of the 
round washing 
H69 
(pmol) 
competitor RNA  
(pmol) 
binding 
time (h) 
elution 
1 
3 times, 0.1% 
Triton-X 
30 90 (tRNA) 2 non-specific 
2 
3 times, 0.3% 
Triton-X 
30 90 (tRNA) 2 non-specific 
3 
10 times, 
0.5% Triton-X 
30 90 (tRNA) 1 non-specific 
4 
10 times, 
0.5% Triton-X 
30 90 (tRNA) 0.5 non-specific 
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PCR products were measured using UV-vis spectroscopy (Nanodrop) at 260 nm. Then, 
to confirm whether the PCR was successful with no contamination, the PCR samples 
were run on a 2% agarose gel in 1  TBE buffer. Finally, the samples were diluted to a 
concentration of 5 µg/µL, and sequenced. 
 
Figure 2.5. A schematic representation of steps before sequencing is shown. 
 
The sequences were found with colony PCR, followed by sequencing on the CEQ8000 
(Beckman Coulter Inc., Pasadena, CA) in the RNA Instrument Room, Wayne State 
University, and Illumina (San Diego, CA) in the DNA sequencing core, Wayne State 
University. Except for the selections carried out at pH 5.5, from each of the selections 
under varying conditions, 20 of the randomly picked colonies were sequenced and 
aligned with ClustalW2 (EMBL-EBI, Cambridge, United Kingdom). For the selections 
done at pH 5.5, 105 randomly picked colonies were sequenced and aligned.  
2.3. Preparation of the peptides  
Peptides were prepared by solid-phase synthesis.71 Rink amide AM resin, NovaSyn 
TGR resin, Fmoc (fluorenylmethyloxycarbonyl)-protected amino acids and O-
benzotriazole-N, N, N’, N’-tetramethyluronium hexafluorophosphate (HBTU) were 
purchased from Novabiochem (Darmstadt, Germany). Diisopropylethylamine (DIPEA), 
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dichloromethane (DCM), dimethylformamide (DMF), piperidine, trifluoroacetic acid (TFA), 
thioanisole, triisopropylsilane (TIPS), ninhydrin, diethyl ether and acetonitrile (MeCN) 
were purchased from Sigma-Aldrich (St. Louis, MO).  
To Rink amide AM resin with a loading level of 0.68 mmol/g in DMF was added 20% 
piperidine in DMF for deprotection, and mixed for 30 min.  After confirmation of coupling 
by a ninhydrin test, the mixture was washed with DMF and DCM (five times each). To 
the Fmoc deprotected resin were added 2 eq. of Fmoc amino acid, 2 eq. of HBTU and 4 
eq. of DIPEA, and the solution was mixed for 4 h. Again, the mixture was checked with 
ninhydrin, and the resin was washed with DMF and DCM (five times each). These steps 
were repeated for each Fmoc amino acid in the sequence. When the peptide of interest 
was completed, the resin was dried and the peptide was cleaved with a cocktail of TFA: 
thioanisole: TIPS: ddH₂O=94: 2: 2: 2 with 2 h incubation (Scheme 1.1). The cleaved 
solution was precipitated and washed with cold ether, centrifuged at 5000 rpm for 30 min, 
and after decanting, the white precipitate was dried in vacuo. The crude peptide was 
then dissolved in ddH₂O and purified by HPLC (Luna C18 reverse phase column 250 × 
10.0 mm, 5 μm, Waters, Milford, MA) on a Waters 600 LC with a 717 autosampler 
(Waters, Milford, MA, USA) and UV-detector by increasing the concentration of MeCN 
from 0 to 40%. The fractions containing product peptide were lyophilized to give a white 
powder. The peptide was then characterized by MALDI-TOF MS (Ultraflex, Bruker, 
Billerica, MA). Positive mode on Ultraflex Extreme TOF/TOF from Bruker (Billerica, MA) 
was used for detection, and 4-hydroxy-α-cyanocinnamic acid (Figure 2.1b) was used as 
a matrix. 
Branched peptides were prepared by solid-phase synthesis as described in the 
previous section. However, the loading of Rink Amide AM resin is 0.68 mmol/g, which is 
too high to synthesize branched peptides.132 Therefore, NovaSyn TGR resin with a 
loading level of 0.31 mmol/g was used, which was purchased from Novabiochem 
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(Darmstadt, Germany). Fmoc-Lys(Fmoc)-OH, Boc-Thr(Trt)-OH, and Fmoc-β-Ala-OH (B) 
were purchased from Novabiochem (Darmstadt, Germany). Fmoc-propargylglycine-OH 
and Fmoc-Lys(ivDde)-OH were purchased from Anaspec (Fremont, CA).  
 
Figure 2.6. Structure of ivDde and the deprotection mechanism is shown. Hydrazine 
removes the protecting group by forming a stable conjugated ring system via Michael 
addition followed by cyclization, which cannot be performed with piperidine, and this 
enables the branched peptide synthesis with different side chains. 
 
Branches were formed using lysine, because both the backbone and side chain have 
amino groups. For branched peptides with the same functional groups on each branch, 
Fmoc-Lys(Fmoc)-OH was used for the synthesis. For branched peptides with different 
peptides growing on each branch, Fmoc-Lys(ivDde)-OH was used.168 Both protecting 
groups Fmoc and ivDde (Figure 2.6) are base-labile, but can be orthogonally 
deprotected. Therefore, they are useful for asymmetric branched peptide synthesis. For 
the synthesis of mixed peptides with different branch sequences, 
(TARHIYBBB)(AAAAAABBB)-Lys-OH,  TARHIYBBB was first added to the backbone 
using Fmoc-protected amino acids except for threonine, where Boc-Thr(Trt)-OH was 
added. Then, 5% hydrazine/DMF was added to remove the ivDde (1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene)isovaleryl) protecting group from the peptide, and the resulting 
slurry was mixed for 30 min, followed by washing. Then, AAAAAABBB was added using 
Fmoc-protected amino acids. The remaining steps, such as cleavage from the resin, 
purification, and characterization were done the same way as described for the 
monomer peptide.  
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Figure 2.7. A general scheme for branched peptide synthesis is shown. 
2.4. Fluorescent intercalator displacement (FID) assay 
TO-PRO®-1 iodide solution (TOPRO, 3-methyl-2-((1-(3-trimethylammonio)propyl)-4-
quinolinylidene)methyl)benzothiazolium) was purchased from Thermo Fisher Scientific 
(Waltham, MA). Potassium hydroxide (KOH) and HEPES were purchased from Fisher 
Scientific (Hampton, NH). Magnesium chloride (MgCl2), sodium cacodylate, neomycin, 
and paromomycin were purchased from Sigma-Aldrich (St. Louis, MO). For the FID 
experiments, a Cary Eclipse Fluorescence Spectrophotometer (Varian, Inc., Walnut 
Creek, CA) and Synergy H1 Hybrid reader (BioTek, Winooski, VT) were used to 
measure fluorescence, with excitation at 500 nm and emission from 510 to 560 nm. To 
the H69 RNA (1 μM) in buffer was added 1 eq. of TOPRO solution, and then the solution 
was titrated with a ligand solution. TOPRO does not exhibit fluorescence in buffer, but 
exhibits strong emission when bound to RNA.138 Each ligand was dissolved in 20 mM 
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HEPES-KOH, 100 mM KCl, 5 mM MgCl2 (pH 7.0) buffer or 20 mM cacodylate, 100 mM 
KCl (pH 5.5) buffer. The ligand samples were prepared at 0, 1, 10, 50, and 100 μM 
concentrations. Each sample was mixed and incubated for 2 min before the 
fluorescence measurement was done. For each experiment, negative controls were 
done with buffer only, samples without H69, samples without TOPRO, and samples 
without peptide. Each measurement was taken and the background spectrum was 
subtracted. Each experiment was performed in triplicate. To calculate the relative 
fluorescence, the fluorescence of the H69 and TOPRO in buffer before ligand addition 
was determined (F0). Then, fluorescence from each sample was measured (F1 to Fn) and 
the relative fluorescence was calculated by setting F0 to 1. The relative fluorescence 
value for each sample was F/F0.   
2.5. Electrospray ionization mass spectrometry (ESI-MS)  
ESI-MS is a method used to obtain an apparent Kd value. This method has been used 
previously for binding studies with RNA and various ligands.118, 120, 169 For most of my 
studies, TriVersa nanospray with LTQ-XL from Advion (Ithaca, NY) was used in the 
Proteomics Core under the direction of Paul Stemmer (Wayne State University). The 
data were processed using Xcalibur (Thermo Fisher Scientific, Waltham, MA), and 
analysis was done on GraphPad Prism (La Jolla, CA). Ammonium acetate (7.5 M, 
NH4OAc) was purchased from Sigma-Aldrich (St. Louis, MO). In this study, the binding 
was done at 10 mM NH4OAc in 50% isopropanol for both pH 5.5 and pH 7.0 conditions, 
1 μM of H69 ΨΨΨ or H69 UUU, and the concentration of peptide varied from 0 to 100 
μM. The salt concentration was lowered due to the limits of the instrumentation. The 
samples were mixed and incubated for 10 min before ESI-MS analysis. Each titration 
experiment was performed in triplicate.  
Since RNA and peptides typically have different ionization efficiencies,147, 170 the 
binding ratios were determined at different charge states and compared. To then 
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determine relative Kd values, a single charge state was chosen for calculating binding 
ratios for a single RNA species (e.g., UUU or ΨΨΨ) with closely related peptide ligands. 
In this study of H69 and peptides, the binding ratios were determined from the peak 
intensities at given m/z values for the (6-) charge state for free RNA and the complex.118, 
169, 171 In other reports, the (5-) charge state was used because of stronger peak 
intensities;118, 169 however, in this study we were not able to use the (5-) charge state 
because the m/z of the RNA (1514) overlapped with the dimer peak of the peptide 
(1514). Therefore, the (6-) charge state of the RNA and the peptide complex was used 
for our studies. To compare the peptide binding to H69 ΨΨΨ and H69 UUU, the ratios of 
the peak areas of free RNA, 1:1, and 1:2 complexes were determined.146, 170  
The apparent dissociation constant of the RNA-peptide binding was obtained by 
plotting the binding ratio to the peptide concentration. The data were plotted on 
GraphPad, using nonlinear curve fitting with the quadratic equation (Equation 2.2). The 
equation correlates the peak area for free RNA (R) and the RNA-peptide complex (RP), 
with the titrated peptide concentration (P). 
Equation 2.2.  
 
 
 
2.6. Surface plasmon resonance (SPR) on BLItz 
SPR is a method used to obtain an apparent Kd value along with kinetic data of binding 
interactions. For these studies, the BLItz system and biosensors from ForteBio (Pall 
ForteBio, Fremont, CA) were used. For the BLItz method, the biosensor was installed 
onto the instrument and was soaked in the buffer for at least 10 min. The samples were 
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prepared by serial dilution, and since the BLItz method is light dependent, the samples 
were placed in black tubes to reduce background light. To the soaked biosensor was 
loaded the target (i.e., biotinylated H69 ΨΨΨ or biotinylated H69 UUU) from a 5 μM RNA 
solution onto the biosensor. The sample (ligand) solutions were prepared by serial 
dilutions from 0, 0.7, 1.5, 3.1, 6.3, 13, 25, 50, to 100 μM in 20 mM HEPES-KOH, 100 
mM KCl, 5 mM MgCl2 (pH 7.0) buffer or 20 mM cacodylate, 100 mM KCl (pH 5.5) buffer. 
The cycles for ligand (peptide) binding included a baseline measurement in buffer for 30 
s, association in ligand solution for 300 s, and dissociation in buffer for 300 s. For 
biomolecular interactions, the response of the optical interference, kon, koff, and Kd values 
were obtained. The experiments were performed in triplicate. 
The apparent dissociation constant of the RNA-peptide binding was obtained by 
plotting the binding ratio to the peptide concentration. The data were plotted on the BLItz, 
using nonlinear curve fitting derived from Langmuir binding (Equation 2.3).  
Equation 2.3.  
 
 
 
 
 
 
2.7. Growth assay 
To determine whether the phage selected have actual effects on E. coli survival, a 
growth assay was performed.172-173 Custom-made phage were prepared by Antibody 
Design Labs (San Diego, CA). As a negative control, SILPYPY, a known artifact 
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sequence that was found in this study, as well as previous studies,119, 174 was also 
prepared. The custom phage grows kanamycin in LB with 60 mg/L. ER2267, a strain 
that is KanR, was obtained from New England Biolabs (Ipswich, MA) and used for the 
growth assay.   
To 100 mL of LB with 60 mg/L of kanamycin was added a single colony of ER2267, 
which was allowed to grow at 37 °C overnight. The overnight culture was diluted 1:1000 
times, then the phage of ~1010 virions/mL was added. After the phage was added, 2 mL 
of the culture was withdrawn at 1, 3, 5, 7, 9, 11, and 24 h, then the OD600 was measured 
on a Synergy H1 Hybrid reader (BioTek, Winooski, VT). 
2.8. Nuclear magnetic resonance spectroscopy (NMR) 
In this study, a 2D 1H homonuclear NMR experiment (2D COSY) was employed to 
observe conformational changes of H69 upon binding. Potassium phosphate (KH2PO4) 
and potassium chloride (KCl) were purchased from Sigma-Aldrich (St. Louis, MO), 
99.96% deuterium oxide (D2O) was purchased from Cambridge isotope laboratories 
(Tewksbury, MA), and ethylenediaminetetraacetic acid (EDTA) was purchased from 
Fisher Scientific (Hampton, NH). 
 Solutions of H69 ΨΨΨ and H69 UUU (50 μM) in NMR buffer (20 mM KH2PO4, 100 mM 
KCl, 1 mM EDTA, pH 5.5 or pH 7.0) were prepared, as well as solutions of H69 ΨΨΨ 
and H69 UUU (50 μM) in the same buffer with peptide 10 times the apparent Kd, 500 
μM). RNAs were renatured by heating the sample to 80 °C for 2 min then slowly cooling 
to RT over 2 h. After renaturing, the respective peptides were added and allowed to 
interact with the RNA for several hours at RT. NMR spectra were recorded using a 
Bruker ADVANCE 700 MHz NMR (Billerica, MA) equipped with a TXI cryoprobe at 298K. 
To determine structural effects of binding, ge-2D COSY was used to analyze JH5-H6 of the 
pyrimidines. Peaks were assigned based off of previously reported values.47, 166 
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CHAPTER 3 – SELECTION OF PEPTIDES BINDING TO H69 AT pH 5.5 USING 
PHAGE DISPLAY AND BINDING STUDIES  
3.1. Biopanning yield and diversity 
Peptides targeting H69 ΨΨΨ at different conditions were selected after four rounds of 
biopanning. In Table 3.1, the yield of each condition is shown. For tRNA, human H69, 
H69 stem, and H69 UUU, the libraries were split after round 3. For rounds 1 and 2, the 
library was incubated in 20 mM HEPES-KOH, pH 7.0, 100 mM KCl, 5 mM MgCl2, 5% 
glycerol, 0.1 mg/mL BSA with 0.1% (v/v) Tween-20 with 30 pmol of H69, and to that was 
added 90 pmol of tRNAPhe as a competitor, which was removed after the incubation time 
of 2 h. Starting with round 3, different competitors were used (Table 3.1), such as 
human H69, H69 stem, and H69 UUU. For pH 5.5 (Table 3.1), the library was incubated 
in 20 mM PBS, pH 5.5, 100 mM KCl, 5% glycerol, 0.1 mg/mL BSA with 0.1% (v/v) 
Tween-20. 
Table 3.1. Yield of each round of phage display with varying competitors. 
round  
competitor RNA 
tRNA (%) 
human 
H69 (%) 
H69 stem 
(%) 
H69 UUU 
(%) 
H69 UUU‡ 
(%) 
pH 5.5 (%) 
1 0.078 0.078 0.078 0.078 0.078 0.001 
2 0.035 0.035 0.035 0.035 0.035 0.025 
3 0.003 0.050 0.35 0.35 0.5 0.80 
4 8.0 10 15 9.0 5.0 0.0005 
‡ specific elution 
The competitors in round 3 were chosen with the hope of finding a peptide that prefers 
H69 ΨΨΨ over human H69, the H69 stem, or H69 UUU. Specific elution was performed 
with H69 UUU. This experiment was designed to find a peptide that has binding towards 
H69 in general, but preferred binding to H69 UUU. To increase the stringency, buffer 
and wash conditions were changed for each step as described in Table 2.1.118, 120 The 
concentration of detergent Triton-X increased from 0.1 to 0.5%, and the number of 
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washes increased from three to ten times, and the incubation time decreased from 2 to 
0.5 h.  
Table 3.2. Diversity of each round of phage display  
round  
competitor RNA 
tRNA  
human 
H69  
H69 stem  H69 UUU H69 UUU‡ pH 5.5  
1 1.6 ˣ 108 1.6 ˣ 108 1.6 ˣ 108 1.6 ˣ 108 1.6 ˣ 108 2.2 ˣ 106 
2 5.5 ˣ 104 5.5 ˣ 104 5.5 ˣ 104 5.5 ˣ 104 5.5 ˣ 104 5.5 ˣ 102 
3 2 27 191 191 273 4 
4 0 3 29 17 14 0 
‡ specific elution 
As described in Table 3.1, the yields from rounds 1 and 2 were 0.078 and 0.035%, 
respectively. At round 3, for tRNA, the yield dropped to 0.003%. For tRNA, the increase 
of number of washes and detergent with the decrease of incubation time led to a 10-fold 
decrease in yield for non-specific elution. At round 4, an increase in yield was observed, 
which is commonly seen in phage selection. The yield decrease followed by an increase 
in biopanning can be explained with the fact that by round 3, the diversity of the library 
decreased from >109 to <102 (Table 3.2). In this study, each round started with a plaque 
forming unit (pfu) of 2 ˣ 1011, which has a diversity of about 1.3 ˣ 109. After the phage 
were eluted, there was a step to amplify the phage so that the total number for the next 
round was 2 ˣ 1011 pfu. At the first round, there were about 100 copies of each phage in 
the library, and as more rounds are performed, the diversity decreased while the number 
of each copy increased. Therefore, by the time the selection reached the 3rd or 4th round, 
we estimated that there were less than 100 diverse sequences. The sequences 
surviving all rounds succeed for various reasons. Some contain strong binding 
sequences for the target, while others are fast growing phage, which amplify faster in the 
E.coli host. The so-called fast growers were also reported in literature. 110, 175 Some 
sequences are selected due to their ability to bind to plastic or streptavidinylated 
magnetic beads, and these are called artifact sequences.176 
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An increase in yield was observed when different competitors were added in round 3, 
such as human H69, H69 stem, and H69 UUU. The yield for human H69 was 0.050%, 
similar to rounds 1 and 2, and the yields for H69 stem and H69 UUU increased to 0.35%. 
By round 4, the yields for biopanning done at pH 7.0 increased to 8-15%. This result 
could be related to the diversity of the library (Table 3.2). The diversity dropped to less 
than 30, and for pH 5.5 conditions or tRNA competitor, the diversity decreased to a 
theoretical number of 0. Therefore, for the pH 5.5 selection, sequencing was performed 
on the phage library from round 3. The low yield for the pH 5.5 selection could also be 
due to the use of more acidic buffers, which have been reported to decrease the survival 
of phage.121 As reported by Derda et al.,110 convergence to a few clones is shown in 
more than 90% of phage display studies, although the drop of diversity leaves many 
questions as to the validity of the phage selected. In biopanning, the target-phage library 
incubation starts with >109 different phage, and after each round, the nonbinding phage 
are washed out. After each round of selection, the phage are amplified so that incubation 
of the library with the target is done with the same number of phage in each round. 
However, this step may be the reason behind the convergence of sequences. Not all 
phage have the same growth rate, and therefore, fast-growing phage that do not 
necessarily bind to the target may be amplified during this step. There is a possibility of 
selecting fast-growing peptides over strong binders. This leads to the conclusion that the 
relative abundance of sequences may not necessarily correlate to the binding affinity, 
which has been shown in previous studies by Abdeen et al.177 To overcome the loss of 
diversity, use of an unamplified library could be considered, but then the ratio of phage 
to target would be needed to be considered. 
3.2. Peptide sequence analysis 
In the first set of conditions used, to check the effect of differing competitors, several 
RNAs such as the stem region of H69, human H69, and tRNAPhe were added. The 
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phage library was incubated in pH 7.0 binding buffer (20 mM HEPES, 100 mM KCl, 5 
mM MgCl2, 5% glycerol, 0.1 mg/mL BSA) and competitors, followed by washing and 
non-specific elution with acidic glycine buffer. After four rounds of selection, 20 randomly 
picked colonies of each condition were sequenced. The selection conditions are 
displayed in Table 2.1.  
 
Figure 3.1. Sequences from randomly picked colonies from the selection with 
competitors human H69, H69 stem, and H69 UUU at pH 7.0 are shown. The upper 
part of the panel displays the sequence of the RNA competitors. The middle part with 
WebLogo 3.3 shows the consensus of the peptide sequences selected, in which the 
size of the sequence shows the frequency of the sequence appearing. The sequences 
of the peptides are aligned on the lower part of the panel. 
 
For all selections, we were able to observe a sequence that shows up more frequently 
than others, FGHYHYA. However, this sequence also appeared frequently in the 
negative control experiment, in which tRNAPhe was used as a competitor with H69 ΨΨΨ 
as a target. From round 3, different competitors were used (Table 3.1), such as human 
H69, the H69 stem, and H69 UUU. These competitors were selected to find a peptide 
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that prefers H69 ΨΨΨ over human H69, H69 stem, or H69 UUU. Peptide SHSLLHH 
appeared three times when human H69 was used as the competitor. The sequence 
SFVLPYY appeared four times when the stem region was used as a competitor. The 
sequence SPPHHND appeared three times when H69 UUU was used as a competitor 
(Figure 3.1). However, the selectivity of the peptides obtained was questionable. If the 
sequence prefers to bind to H69 UUU over H69 ΨΨΨ, the sequence would be expected 
to appear with the specific elution with UUU, not when H69 UUU was used as a 
competitor. These results imply that the sequences may bind to the loop region of the 
target H69.  
For specific elution with UUU, six different sequences were obtained. Sequence 
FGHYHYA appeared 12 times, while FAPYNHA, WATQHWA, WPTLQWA, LASHTAP, 
and KILGWSG were each observed once. In this case, the main peptide was FGHYHYA, 
which was also found in the selections at pH 7.0 with differing competitors as described 
above. Unfortunately, this sequence may be a fast grower and lacking selectivity for H69. 
Therefore, the sequences screened in this study were most likely fast-growing phage, 
which could also explain the presence SILPYPY, another sequence reported in the 
literature as a fast-grower.110, 119 For these reasons, we did not pursue further studies 
with these sequences.  
In the 4th round, the yield was >5% for the non-specific elution conditions at pH 7.0. 
For the selection at pH 5.5, the yield was still very low (0.0005%) after the 4th round, but 
a consensus was still obtained from the sequence alignment (Figure 3.2). The poor yield 
may be a result of amplification of sequences that are harmful to the host bacteria. While 
performing biopanning, there is a possibility of target-unrelated sequences being 
selected. Among the phage, some of them are prone to propagate faster than others, 
which would lead to their selection. Therefore, the peptide sequences were checked with 
the literature and SAROTUP, a program that searches for target-unrelated peptides 
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developed by Huang et al.176 Among the sequences shown, none of them are known for 
binding to streptavidin or to be target-unrelated peptides.176 However, three sequences, 
SAPHHND, SPPHHND, and SRAHHIA, turned out to be fast-growing peptides. Also, 
sequences SILPYPY and HAIYPRH were reported previously to be artifact 
sequences.110, 119  
 
Figure 3.2. Sequences selected at pH 5.5 were aligned. Compared to sequences 
screened under pH 7.0 conditions, these sequences contained more polar residues.  
 
In the third set of conditions, when the buffer conditions were altered, we observed 
some differences in the selected peptides. Previous work showed that the H69 
conformation changes with the Mg2+ concentration.66-67, 178 To determine whether there 
are different sequences screened under differing Mg2+ concentrations or pH conditions, 
phage display was conducted at pH 5.5 in PBS. After four rounds, 105 randomly picked 
colonies from each condition were sequenced. The conditions are displayed in Table 2.3. 
The sequences from the pH 5.5 selection showed a consensus. The sequences were 
sorted, as shown in Figure 3.2. Peptides SILPYPY, SAPHHND, and SHSLLHH that 
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were observed in higher pH buffer selections appeared three, three, and one time(s), 
respectively. The sequence FGHYHYA that appeared in pH 7.0 buffer conditions was 
not found in this selection. TPARHIY appeared 38 times out of 105 sequences. 
Table 3.3. Sequences selected for further studies176 
 
Overall, from the sequence analysis we cannot determine whether the goal to find 
phage that selectively bind to H69 in a closed conformation was achieved or not. 
However, the sequence TPARHIY that appeared 38 times was only observed from pH 
5.5 selections (Figure 3.2). For further studies, peptides in Table 3.3 were chosen 
based on the selections done at pH 5.5 buffer conditions, and the alignments in Figure 
3.2, with at least one sequence from each family. Also, if the selected peptides were also 
found under pH 7.0 buffer conditions, they are listed in Table 3.3. These peptides are 
unlikely to have selectivity for H69 ΨΨΨ over H69 UUU, but may have potential binding 
to either form of H69.  
54 
 
 
3.3. Preparation of RNA 
The RNAs H69 ΨΨΨ and H69 UUU were prepared as mentioned in Section 2.1. In 
Figure 3.3a, the 20% polyacrylamide gel is shown after purification and desalting of the 
RNAs, which was also verified by MALDI-TOF (Figure 3.3b). 
 
 
Figure 3.3. Representative data of purified H69 ΨΨΨ and H69 UUU are shown. a) 
Isolated H69 on a 20% polyacrylamide gel is shown. b) The MALDI-TOF spectrum of a 
purified H69 ΨΨΨ is given. The predicted mass of H69 (M+H)+ is 6060.7 Da. 
 
 
3.4. Preparation of peptides 
Selected peptides were synthesized using solid phase peptide synthesis as 
described in Section 2.5. The structures of the peptides are shown in Figure 3.4. 
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Figure 3.4. Structures of the amidated peptides used in this thesis work are shown 
(with protonation states at pH 7.0). The peptides are all positively charged. 
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The sequences display positive charges at both pH 5.5 and pH 7.0 conditions. In 
comparison to previous selections that found neutral and positively charged 
peptides,118-120 these peptide sequences contain amino acids with more charges or 
greater hydrophilicity. Out of 14 peptides in Figure 3.4, 10 of them contain one or 
more histidines, which is neutral at pH 7.0 and positively charged at pH 5.5. This 
may have resulted from the selection being carried out at lower pH and the target 
being a negatively charged RNA, which attracts the positively charged peptides. 
 
Figure 3.5. The MALDI-TOF spectrum (a) and HPLC trace (b) of purified TARHIY are 
shown. The other peptides are displayed in Appendix A. 
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During the synthesis, peptide TARHIY (Figure 3.5) was also obtained in addition to 
TPARHIY (Figure 3.4b). Since proline has a secondary amino group, it is difficult to 
tell from a Kaiser test179 if it has been incorporated into the peptide (Figure 3.6). The 
major peptide product was shorter than the heptamer peptide screened from phage 
display, which happens to make it more druggable according to literature precedence 
with small peptide drugs.180 Therefore, the TARHIY peptide was used for subsequent 
binding and biological experiments. The peptides were HPLC purified and 
characterized by MALDI-TOF.  
 
 
Figure 3.6 Kaiser test with primary and secondary amino acids is shown.179  
 
3.5. Screening peptides with the FID assay 
The FID assay was performed under buffer conditions that were used previously.138 
The dye, TOPRO, bound to H69 and demonstrated increased fluorescence upon 
interaction with the RNA. If a ligand displaces the dye, the fluorescence is then expected 
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to decrease. The change in fluorescence can be therefore used to estimate relative 
binding affinities of ligands to RNA. The concentration of the ligands varied from 0 to 100 
μM. In this study, displacement of fluorescence was determined by the addition of 
neomycin as a control, and then the selected peptides with H69 UUU or H69 ΨΨΨ were 
tested. There was little dye displacement by most of the peptides (less than 5%). The 
low change in fluorescence upon addition of peptide to the TOPRO-RNA complex was 
noticeably different from the response with neomycin, a known H69 binder. The 
fluorescence decrease observed with neomycin titration was consistent with results from 
previous studies employing 2-aminopurine-incorporated H69.67 The lack of fluorescence 
change can be interpreted as a lack of peptide binding, or another mechanism such as 
peptide binding to the complex without dye release, or peptide binding to the dye alone. 
Some of the peptides, such as TARHIY, TPARHIY, SHSLLHH, and RQVANHQ 
exhibited some displacement at higher concentrations (>50 μM) (Figure 3.7). The 
displacement was most apparent when the ratio of [RNA]:[TOPRO] was 1:1. 
Interestingly, however, the shortened peptide TARHIY, showed greater displacement of 
TOPRO than the phage-selected peptide TPARHIY. TARHIY showed displacement of 
TOPRO up to 28% at 100 µM.  
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Figure 3.7. FID assay of peptides against H69 ΨΨΨ and H69 UUU at pH 5.5 and pH 
7.0. For pH 7.0, 20 mM HEPES, 5 mM MgCl2, 100 mM KCl buffer was used. For pH 
5.5, 20 mM cacodylate, 5 mM MgCl2, 100 mM KCl buffer was used. The assay was 
performed in triplicate (1:1 ratio of RNA:TOPRO, 1 µM each). 
The specificity of TARHIY towards H69 was examined by carrying out the binding 
experiment with tRNAPhe. Neomycin was also used as a control, because it is known to 
bind to tRNAPhe. Displacement of fluorescence by the addition of neomycin at both pH 
7.0 (Figures 3.8b and 3.8c) and pH 5.5 (Figure 3.8d and 3.8e) conditions, with either 
100 mM KCl present (Figures 3.8c and 3.8e) or none (Figures 3.8b and 3.8d). Salt in 
physiological buffers play an important role in RNA structures and interactions; therefore, 
binding events of the peptide or neomycin to tRNAPhe in varying ionic strengths was 
examined. Both Mg2+ and K+ play important roles, however, only the concentration of K+ 
was varied in this study because Mg2+ is reported to play important roles in RNA 
folding.181 The dye TOPRO is reported to interact with bulges of RNA, therefore, 
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maintaining the folded structure is important in this assay.138, 182 For the same reason, 
although no Mg2+ was present in the phage selection at pH 5.5, buffers used at both pH 
5.5 and pH 7.0 contained Mg2+.  
 
Figure 3.8. Salt dependence of neomycin and TARHIY against tRNAPhe at pH 5.5 and 
pH 7.0. For pH 7.0, 20 mM HEPES, 5 mM MgCl2, 100 mM KCl buffer was used, and 
for pH 5.5, 20 mM cacodylate, 5 mM MgCl2, 100 mM KCl buffer was used, wherein 
less salt (b and d) conditions indicate no potassium and regular salt (c and e) 
conditions indicate 100 mM KCl. The assay was performed in triplicate (1:1 ratio of 
RNA:TOPRO, 1 µM each). a) The structure of tRNAPhe is shown. b-e) Results of the 
FID assay with neomycin and TARHIY in the presence of tRNAPhe are shown.  
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At higher concentrations of the ligands (>50 µM), the salt concentration made little 
difference (<3%) in displacement of dye at both pH values. At pH 7.0, neomycin 
exhibited a 1.5-fold lower change of fluorescence compared to studies done at pH 5.5, 
suggesting less binding to the RNA. At lower concentrations of neomycin (1 and 10 µM), 
less binding to tRNA was observed when either the salt concentration or pH were raised 
(up to 20%). The impact of salt on neomycin binding to tRNAPhe is not surprising given 
that the binding mode involves electrostatic interactions. Unlike neomycin, in less salt 
conditions without K+ ions present, TARHIY showed little dye displacement (<5% 
decrease in fluorescence at 100 µM) with addition of the peptide (Figure 3.9), and no 
significant preference for buffer conditions. However, with 100 mM KCl present, upon 
TARHIY titration at 50 and 100 μM, the dye displacement would increase up to 20 and 
28%, respectively. The difference caused by the presence of K+ may be due to the salt 
playing an important role in folding of the RNA, wherein K+ may stabilize specific RNA 
structures. This may also provide some information on the binding mode of the peptide. 
If the peptide binds to H69 through an electrostatic manner, the structure of H69 would 
be sensitive upon binding of the peptide that would change the secondary structure. This 
assay is based on TOPRO interacting with the RNA in a certain secondary structure, 
and if the structure is too flexible, addition of peptide may not impact the structure and 
cause TOPRO displacement. If the structure is rigid, addition of peptide would be 
expected to cause displacement of the dye. 
A salt dependence study was also performed with H69 ΨΨΨ and H69 UUU (Figure 
3.9). The salt concentration may impact ligand interactions either directly or indirectly 
(i.e., RNA structural changes may affect ligand binding). In the absence of potassium, 
the dye displacement was enhanced with neomycin at all concentrations (up to 25%), 
but not with TARHIY for both H69 constructs at lower ligand concentrations (<50 µM). 
The results for neomycin and H69 were consistent with the results for tRNAPhe. For 
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TARHIY, fluorescence quenching was only observed at higher concentrations of the 
peptide (50 and 100 µM, up to 18%).  
A pH dependence study was also performed with H69 ΨΨΨ and H69 UUU (Figure 
3.9). At pH 5.5, 2-fold enhancement in dye displacement was observed with neomycin 
(at all concentrations) and TARHIY (at higher concentrations, 50 and 100 µM) compared 
to pH 7.0. However, no preference for H69 type was observed. At higher concentrations 
of the peptide (50 and 100 µM, up to 18%) at pH 5.5 conditions, a minor difference was 
observed upon TARHIY binding.  The phage selection was done at pH 5.5 with no Mg2+, 
so the conditions of this assay were different (5 mM Mg2+). We hoped to find a peptide 
that preferred the closed-conformation, and at pH 5.5, the absence of Mg2+ was reported 
to favor this conformation.67 The presence of Mg2+ in this assay may have induced a 
mixed conformation, resulting in only a small difference between the pH conditions. 
However, although the peptide did not show selectivity between H69 ΨΨΨ and H69 UUU, 
a very modest selectivity of H69 over tRNAPhe can be observed if the data in Figures 3.8 
and 3.9 are compared. Lastly, the peptide caused little fluorescence change (up to 28% 
at 100 µM), while neomycin showed displacement up to 90% at 100 µM.  
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Figure 3.9. Salt dependence of neomycin and TARHIY against H69 ΨΨΨ and H69 
UUU at pH 5.5 and pH 7.0. For pH 7.0, 20 mM HEPES, 5 mM MgCl2, 100 mM KCl 
buffer was used, and for pH 5.5, 20 mM cacodylate, 5 mM MgCl2, 100 mM KCl buffer 
was used, wherein less salt (b and d) conditions indicate no potassium and regular salt 
(c and e) conditions indicate 100 mM KCl. The assay was performed in triplicate (1:1 
ratio of RNA:TOPRO, 1 µM each). 
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3.6. Binding studies with ESI-MS 
The goal of ESI-MS experiments was to determine the binding affinity and selectivity of 
the peptide TARHIY towards H69 ΨΨΨ and H69 UUU at differing buffer conditions (i.e., 
varying pH), and obtain apparent Kd values and stoichiometries. Previous studies have 
shown that ESI-MS is a method useful to obtain apparent Kd values for peptide-RNA 
complexes.118, 120, 169 The dissociation constant obtained from this study is relative, not 
absolute, due to the ionization efficiencies being different between RNA and peptide. 
Furthermore, the decrease of free RNA was not directly related to the increase of the 
RNA-peptide complex formation (Figures 3.10 to 3.13), because the (4-) charge state 
for the RNA overlapped with the dimer peak of the peptide. In this thesis work, the 
binding was measured at 10 mM NH4OAc for both pH 5.5 and pH 7.0 conditions, which 
is lower than the salt concentration used for selection. The salt concentration employed 
was lower due to the instrumentation limits; however, the data quality was still poor due 
to background salt in the samples, which is more apparent in low salt buffers. Despite 
much effort to purify them, the peptide samples contained residual salt after HPLC. Each 
experiment was performed in triplicate.  
Since the RNA and peptides have different ionization efficiencies, the binding ratios 
were different for each condition tested. Therefore, conditions were carefully controlled 
in order to compare and get relative binding information for different RNAs or peptides. 
The binding ratio was calculated by comparing the (5-) charge states for both RNA and 
complex. Although the (4-) charge state of H69 showed a stronger signal than other 
charge states, we were not able to focus on this charge state because it matched the 
dimer peak of the peptide (Figures 3.10 to 3.13). Therefore, the (5-) charge state of the 
RNA and the complex were used for these studies to determine the peak areas and 
relative free and bound concentrations. 
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Figure 3.10. Representative ESI-MS results for TARHIY titration at pH 5.5 against H69 
ΨΨΨ are shown. In the spectra, complexes of 1:1 and 1:2 (H69 ΨΨΨ:peptide) binding 
ratios are observed. The experiments were performed in triplicate at 10 mM NH4OAc 
(pH 5.5). 
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Figure 3.11. Representative ESI-MS results for TARHIY titration at pH 5.5 against H69 
UUU are shown. In the spectra, complexes of 1:1 and 1:2 (H69 UUU:peptide) binding 
ratios are observed. The experiments were performed in triplicate at 10 mM NH4OAc 
(pH 5.5). 
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Figure 3.12. Representative ESI-MS results for TARHIY titration at pH 7.0 against H69 
ΨΨΨ are shown. In the spectra, complexes of 1:1 and 1:2 (H69 ΨΨΨ:peptide) binding 
ratios are observed. The experiments were performed in triplicate at 10 mM NH4OAc 
(pH 7.0). 
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Figure 3.13. Representative ESI-MS results for TARHIY titration at pH 7.0 against H69 
UUU are shown. In the spectra, complexes of 1:1 and 1:2 (H69 UUU:peptide) binding 
ratios are observed. The experiments were performed in triplicate at 10 mM NH4OAc 
(pH 7.0). 
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The apparent Kd values as given in Table 3.4 were obtained using the quadratic 
equation. The fraction of RNA-peptide complex to free RNA was plotted using GraphPad 
(Figure 3.14). The RNA-peptide complex did not reach saturation most likely because 
the ionization efficiencies of the RNA-peptide complexes are much lower than that of the 
free RNA. Despite these limitations, we could gain knowledge about relative binding 
affinities. The peptides showed moderate (low μM) binding to both H69 ΨΨΨ and H69 
UUU. As with the FID studies, no significant selectivity between the modified and 
unmodified RNA was observed. Although the binding affinity (μM) of the peptide to RNA 
may appear low compared to protein-drug interactions (nM), it should be pointed out that 
aminoglycosides, which are effective ribosome-targeting antibiotics, bind with similar 
affinity to rRNA (low μM) and with very poor selectivity.  
When the titrated peptide concentration exceeded 20 μM, a complex of peptide dimer 
bound to RNA was detected, which may imply an aggregation or more than one binding 
site of the peptide. These results led to studies of multimeric peptide binding studies with 
H69 (Chapter 4). 
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Figure 3.14. ESI-MS results for TARHIY at 10 mM NH4OAc (pH 5.5 and pH 7.0) 
against H69 ΨΨΨ and H69 UUU. a) The titration curves for TARHIY bound to H69 
ΨΨΨ and H69 UUU (y axis: binding ratio of at (5-) charge state) at different buffer 
conditions (pH 5.5 vs. pH 7.0) are shown.  
 
Table 3.4. Apparent dissociation constants (Kds) obtained from ESI-MS. The apparent 
dissociation constants (Kd values) were obtained by fitting relative binding ratios with a 
quadratic equation. 
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3.7. Binding studies with SPR 
SPR is a method used to obtain apparent Kd values in solution phase by monitoring 
interactions of the surface of a CM5 chip.183 This method does not need a tag on the 
peptide, and the binding event is detected by monitoring the change in response unit. 
The response unit is derived from alteration of the refractive index of the chip upon 
binding. To a CM5 chip was immobilized streptavidin, followed by immobilization of 
biotinylated H69 ΨΨΨ. To reduce nonspecific binding after immobilization of the 
biotinylated H69 ΨΨΨ, biotin was passed through the cells to coat any exposed 
streptavidin sites. Following H69 immobilization, the TARHIY concentration was varied 
from 0 to 100 μM in both pH 5.5 (20 mM PBS, 100 mM KCl) and pH 7.0 (20 mM HEPES, 
100 mM KCl, 5 mM MgCl2) buffers. Each experiment was performed in triplicate. Since 
the mass of the peptide (758 Da) was smaller compared to H69 (6060 Da), the response 
unit change was small, but significant. This was the first time in our laboratory that we 
were able to monitor peptide binding to H69 using SPR. However, the signal was only 
detectable under pH 5.5 conditions, possibly due to nonspecific charge-charge 
interactions between the positively charged peptide (pI=9) and negatively charged 
streptavidin (pI=5) under pH 7.0 conditions. In Figure 3.15, curves obtained from 
streptavidinylated surfaces exhibit a sharp increase immediately after injection followed 
by a flat line, while curves obtained from avidinylated surfaces exhibit a more gradual 
increase following the initial injection. Avidin (pI=10.5) was used instead of streptavidin in 
an attempt to detect binding at pH 7.0, but was unsuccessful (Figure 3.15). A binding 
affinity of 27 µM was obtained with streptavidinylated surfaces, and 11 µM with 
avidinylated surfaces (2.5-fold tighter binding). Although the phage were selected using 
streptavidinylated magnetic beads, the Kd value obtained with avidinylated surfaces (11 
µM) matched more closely with the Kd value obtained with ESI-MS (10 ± 2 µM).   
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Figure 3.15. SPR results for TARHIY at pH 5.5 (20 mM cacodylate, 100 mM KCl, and 
0.1% Tween-20) against H69 ΨΨΨ with a) streptavidin or b) avidin. The curves shown in 
color correspond to measurements of a two-fold serial dilution of the peptide ligands 
over a concentration range. The curves in black correspond to global fits in 1:1 binding 
model (R2>0.88). 
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The kinetics of the binding events with streptavidin or avidin revealed difference 
between the two proteins immobilized to the CM5 chip. For streptavidin, kon of 4.2e3 Ms
-1 
and koff of 2.7e-5 s
-1 values were obtained, compared to kon of 13 Ms
-1 and koff of 0.02 s
-1 
for avidin. A higher kon was observed with streptavidin, implying a fast nonspecific 
charge-charge binding interaction of the peptide to H69. The apparent binding affinities 
obtained from kon and koff appeared to be unusually high or low (6.4 nM for streptavidin 
and 1.4 mM for avidin). Furthermore, poor fitting was observed in both cases, implying 
that the binding of TARHIY to H69 is not through 1:1 binding. 
3.8. Binding studies with BLItz 
The goal of BLItz studies was to determine the binding affinities of peptide TARHIY to 
H69 in pH 5.5 and pH 7.0 buffer conditions and compare to other methods. Similar to 
SPR, this method is useful for monitoring binding events in situ, and can be used to 
obtain kinetic information as well as determining the binding constants.  
Previous studies have shown that BLItz results correlate with SPR,162 likely because of 
the similar detection method. One major difference between BLItz and SPR is the mode 
of association and dissociation. SPR has the biosensor immobilized onto a chip and 
there are flow channels that the ligands and analytes flow through. Therefore, for 
association and dissociation, a buffer solution containing a target or ligand is constantly 
flowing over the chip. This process may cause mass transport, but the concentration of 
the solution stays constant during the process. BLItz uses a biosensor that is 
immobilized onto a tip that is dipped into a tube containing a buffer solution with a target 
or ligand. The instrument is designed to constantly shake the tube so that the solution 
around the biosensor is not just monitoring diffusion.162, 184 Association and dissociation 
in this method is done in the same solution into which the biosensor is dipped, with 
concentrations of the target or ligand increasing or decreasing manually. Therefore, for 
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binding studies with molecules sensitive to the concentration, it is necessary to use large 
volumes (250-300 µL) of the solution of interest to minimize error.  
In Figure 3.16, binding curves obtained from BLItz and dissociation constants are 
shown. The peptide ligand, which has a mass of 1/8th of the immobilized RNA, produced 
a small change in signal in SPR. With the use of BLItz, the change in signal was more 
apparent, as shown in Figure 3.16. (Expanded figures are displayed in Appendix B) 
 
Figure 3.16. BLItz binding curves for TARHIY at pH 5.5 (20 mM cacodylate, 100 mM 
KCl, and 0.1% Tween-20) and pH 7.0 (20 mM HEPES-KOH, 100 mM KCl, 5 mM 
MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ and H69 UUU. The curves shown in 
color correspond to measurements of a two-fold serial dilution of the peptide ligands 
over a concentration range of 0 to 100 μM. The curves in black correspond to global 
fits in 1:1 binding model. The experiments were performed in triplicate. The expanded 
figures are displayed in Appendix B. 
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Examining the kinetics of the binding events revealed similar kon and koff values for 
TARHIY binding to H69 ΨΨΨ and H69 UUU at pH 5.5 and pH 7.0. The average kon and 
koff values are given in Table 3.5. In these cases, poor fitting and large errors were 
observed, both by the sensogram (Figure 3.16 and Appendix B) and the rate constants 
(Table 3.5), implying that the binding of TARHIY to H69 is probably not through a simple 
1:1 binding mode.  
Table 3.5. Rate constants (kon and koff) obtained from BLItz 
 
The apparent dissociation constants obtained from BLItz are reported in Table 3.6. 
The apparent dissociation constants were ~15 µM, which did not show a significant 
preference for RNA type or pH value. The binding affinities obtained with this method in 
physiological buffers, which were used in the phage selection, agree well with the data 
from ESI-MS. As mentioned earlier these values also demonstrate moderate affinity of 
the peptide for H69, which matches that of some natural antibiotics that target H69. 
Table 3.6. Apparent dissociation constants (Kds) obtained from BLItz 
 
3.9. NMR spectroscopy 
In this study, 2D 1H homonuclear NMR experiments (2D gCOSY) were employed to 
examine the binding of TARHIY to H69. Crosspeaks between the H5-H6 protons on the 
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pyrimidines of H69 were observed. If the ligand binds to H69, the local chemical 
environments of nuclei on H69 may be altered by the ligand directly if it binds in 
proximity or changes the local H69 RNA conformation upon titration with peptide. 
Overlays of NMR spectra of H69 obtained with TARHIY are shown in Figures 3.17 to 
3.19.  
 
Figure 3.17. Overlay of the NMR spectra for H69 UUU in the absence (black) or 
presence (grey) of TARHIY at pH 5.5. The concentrations of RNA and peptide were 50 
and 500 μM, respectively. The arrow indicates the chemical shift change and direction 
at C1914. The NMR spectra were obtained by Evan Jones. 
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Figure 3.18. Overlay of the NMR spectra for H69 ΨΨΨ in the absence (black) or 
presence (grey) of TARHIY at pH 5.5. The concentrations of RNA and peptide were 50 
and 500 μM, respectively. The arrow indicates the chemical shift change and direction 
at C1914. The NMR spectra were obtained by Evan Jones. 
 
Figure 3.19. Overlay of the NMR spectra for H69 UUU in the absence (black) or 
presence (grey) of TARHIY at pH 7.0. The concentrations of RNA and peptide were 50 
and 500 μM, respectively. The arrow indicates the chemical shift change and direction 
at C1914.The NMR spectra were obtained by Evan Jones. 
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Upon addition of TARHIY at pH 5.5 conditions, changes in the chemical shifts were 
observed at C1914 (Figure 3.17) and C1920 (Figure 3.18) for H69 ΨΨΨ and H69 UUU, 
respectively. The chemical shift change in H69 UUU at C1914 and U1915 was less than 
0.02 ppm (Figure 3.17), whereas the change at C1920 for H69 ΨΨΨ was ~0.04 ppm. 
For H69 ΨΨΨ at pH 5.5, the C1914 crosspeak was not detected, possibly due to 
structural dynamics (Figure 3.18). The changes upon peptide binding imply alterations 
in the chemical environment around those residues. Residue C1914 is located in the 
loop region of H69, and C1920 is at the stem-loop transition region. The results imply a 
direct interaction with TARHIY or an induced conformation change at these regions due 
to peptide binding. Residue C1914 was shown in previous studies to participate in base 
stacking with Ψ1915.48, 185 This is the first time that we observed interactions in the loop 
region of H69 by a small molecule. Previous studies with DMS probing suggested that 
the RNA structure involves A1913 existing in a stacked-in  (less solvent exposed) 
conformation at lower pH (pH 5.5) and lower Mg2+ concentrations (1 mM).178 The buffer 
conditions for the selection experiment was at pH 5.5 with no Mg2+ (20 mM KH2PO4, 100 
mM KCl, 1 mM EDTA, pH 5.5 or pH 7.0).178 The concentrations of RNA and peptide 
were 50 and 500 µM, respectively. 
The spectrum of H69 UUU with TARHIY at pH 7.0 is shown in Figure 3.19. No change 
in the chemical shifts were observed in this case. The binding studies discussed in 
previous sections revealed that there was no apparent difference in binding affinity to 
H69 ΨΨΨ or H69 UUU regardless of the solution pH. The NMR results suggest that 
binding of the peptide to H69 UUU at pH 7.0 changes the local RNA conformation which 
was not observed for H69 ΨΨΨ. From previous studies, it was shown that a decrease in 
the pH value may induce increased stacking of the loop region in H69 ΨΨΨ.67, 178 The 
peptide may bind to the loop, but the stacking interactions may not be impacted enough 
to observe a change in the NMR spectrum. 
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3.10. Growth assay 
To determine whether the selected phage have effects on survival of E. coli, a growth 
assay was performed. Custom phage displaying peptides TARHIY and TPARHIY were 
prepared to determine whether there is a difference between the two sequences with 
respect to bacterial growth. A known artifact sequence SILPYPY, which was found in 
this study and previous studies, was used as a negative control.175 The custom phage is 
KanR, and since kanamycin does not interfere with H69 function, the growth was 
predicted to be dependent on the phage present. The custom phage were grown with 
kanamycin at 60 mg/L in LB media. The bacterial strain ER2738 used for phage display 
was TetR, therefore the custom phage would not grow in ER2738. Instead, ER2267, a 
phage strain that is KanR, was used for the growth assay.   
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Figure 3.20. Growth assay results are shown. To media containing ER2267, ~1010 
virions of phage were added and their effect on growth was monitored. Values are 
average values of three measurements. Except for the measurement with SILPYPY 
(18% error) at 24 h, each measurement exhibited a small difference (<3%). The data 
were fitted with GraphPad.  
 
The goal of this assay was to examine growth impact of the selected phage. The 
selected phage (TARHIY) reduce the growth at 24 h by 40% compared to the control 
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with no phage infection. However, for the other phage studied (TARHIY, TPARHIY, 
HITSTRY, and SILPYPY), a decrease (<20% at 24 h) in growth was observed. At 24 h, 
compared to SILPYPY, a peptide that was selected in previous studies to be a fast 
grower, peptides TPARHIY and TARHIY showed 20% decrease in growth. Compared to 
HITSTRY, another peptide that was selected during this selection, peptides TPARHIY 
and TARHIY showed 10% decrease in growth. However, the difference was not 
significant, and no phage showed more than 40% decrease in growth, which may reveal 
some information of the selected phage. As discussed in Sections 3.1 and 3.2, the 
phages selected through phage display may be fast growers in general, because phage 
causing complete growth inhibition would never be selected. The phage encoding 
TARHIY and TPARHIY showed similar growth, implying that the proline may not impact 
the peptide activity. The TPARHIY peptide was selected from phage display and 
appeared 38 times out of 105 sequences, indicating that it overpowered other fast-
growing phage. In contrast, the TARHIY peptide was discovered through the binding 
analysis following selection. Nonetheless, they appear to have similar activity in the 
growth assay.  
3.11. Competition studies of peptide TARHIY and neomycin to H69 using BLItz 
Previous studies have shown that neomycin interacts with the stem region of H69.186-
187 For ribosome recycling, RRF interacts with H69, which then separates H69 from 
forming B2a intersubunit of the 70S ribosome.32, 61, 186, 188 Rings I and II of neomycin was 
shown to be bound to H69 at residues G1921-C1924 and G1906 (Figure 3.21), which 
alters the conformation of H69.186  The interaction between H69 and RRF was shown to 
be disrupted upon binding of 2-DOS, leading to inhibition of ribosome recycling.186 
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Figure 3.21. A chemical structure of neomycin and crystal structure (PDB ID: 4V52) of 
H69 and neomycin is shown.  
 
In previous sections, a peptide TARHIY was derived from a sequence selected from 
phage display, which exhibited a moderate binding to the loop region of H69. Through 
ESI-MS and BLItz, the peptide exhibited moderate binding to H69. A Scatchard analysis 
of ESI-MS data implied there is cooperative binding of the peptides to H69. The primary 
binding site was the H69 loop region. Therefore, peptide TARHIY binding to H69 in the 
presence of neomycin was explored. The peptide, TARHIY was shown to have binding 
to the loop region of H69, while neomycin was shown in previous studies to bind to the 
stem region of H69, so we were curious to know if both ligands could bind 
simultaneously to H69. 
3.11.1. Design of binding assay of neomycin and TARHIY to H69 using BLItz 
In previous chapters, biotinylated H69 was immobilized to a streptavidinylated surface 
to select peptide ligands and to monitor the binding of ligands, such as monomer 
peptides or dimeric peptides in buffer, using SPR or BLItz. However, to monitor dual 
binding of neomycin and peptide TARHIY, immobilization of the RNA followed by binding 
of ligands (neomycin or peptide TARHIY) may not be able to show dual binding modes. 
Therefore, to monitor dual binding of neomycin and peptide TARHIY to H69, instead of 
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immobilizing the target, H69, a biotinylated peptide TARHIY was immobilized onto the tip, 
followed by association of free H69. After the H69 association step, we monitored the 
biosensor in a secondary association step in buffer, then solutions containing neomycin 
or peptide TARHIY, or the free RNA (Figure 3.22). 
 
Figure 3.22. A schematic design of a BLItz experiment to monitor dual binding of 
peptide and neomycin to H69 is shown. a) Sensor preparation with peptide 
immobilization is illustrated. b) The first association of H69 is represented. c) The 
second association of neomycin is shown. d) A schematic sensogram of steps a) to c) 
is shown. 
 
To immobilize the peptide onto a streptavidinylated biosensor, a biotinylated peptide 
TARHIY was synthesized. A schematic description of the synthesis is shown in Scheme 
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3.1. By utilizing a orthogonally protected Fmoc-Lys(ivDde)-OH, peptide TARHIY was 
synthesized onto the α-amino group, followed by attachment of biotin onto the ε-amino 
group. The peptide was then cleaved with a cleavage cocktail described in Chapter 2, 
followed by purification with HPLC. The structure and MALDI-TOF spectrum of the 
purified biotinylated peptide TARHIY is shown in Figure 3.23.  
Scheme 3.1. Scheme of synthesis of biotinylated peptide TARHIY 
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Figure 3.23. MALDI-TOF spectrum of biotinylated peptide TARHIY is shown. 
 
3.11.2. Binding of neomycin and TARHIY to H69 using BLItz  
To monitor possible dual binding of neomycin and TARHIY to H69, BLItz was used. To 
a streptavidinylated sensor, biotinylated peptide TARHIY (Bi-TARHIY) was immobilized, 
followed by binding events at pH 5.5. The RNA H69 UUU (1 μM) in 20 mM PBS, 100 KCl 
was then added, followed by incubation with buffer, neomycin (1 μM), or free peptide 
TARHIY (10 μM) in buffer. The concentration of neomycin solution and peptide TARHIY 
was based on the Kds observed in previous studies. The sensogram is shown in Figure 
3.24. In theory, if the binding sites of neomycin and peptide TARHIY are independent 
from each other, one would expect to see a sensogram such as Figure 3.24b, which 
shows increase in signal when neomycin binds, and decrease in signal in buffer. 
However, the buffer showed similar dissociation curve compared to the free peptide, 
while neomycin showed a steep decrease in dissociation. This result indicates that 
although the primary binding sites are different, the binding modes of the two molecules 
to H69 UUU are not independent. In this case, neomycin and TARHIY appear to have 
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competitive binding to H69, or allosteric binding of one ligand impacts binding by the 
second ligand.  
 
Figure 3.24. BLItz sensogram and table indicating each step incubation of peptide 
biotinylated TARHIY, RNA H69 UUU, and neomycin are shown. a) Overlay of 
sensograms are shown. b) A description of each sensogram is shown with the 
incubation conditions for each step.  
 
 
Another BLItz sensogram indicating the correlation of the binding sites of the ligands 
towards H69 is shown in Figure 5.6. This sensogram shows a binding event of H69 with 
the two ligands differently from Figure 5.5. In Figure 5.6, Bi-UUU is immobilized to the 
bionsensor prior to the ligands binding. At step 4, either neomycin or peptide TARHIY 
was added, and in step 5, a different ligand was added. The data shown do not reveal a 
Kd or total displacement that can show the binding sites overlap. However, the final 
equilibrium response of the binding curves shows different levels when neomycin is 
added relevant to the order of addition. When the peptide is added first followed by 
addition of neomycin, the equilibrium response is lower compared to vice versa.  
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3.12. Conclusions 
In this chapter, phage display was done to find a peptide that has selective binding to 
H69 ΨΨΨ at pH 5.5. The peptides selected did not reveal a preference for H69 ΨΨΨ 
over UUU as hoped, but the peptide TPARHIY revealed a moderate preference for H69 
over tRNAPhe. A truncated version, TARHIY was shown in the FID assay to have better 
affinity for H69 than the selected peptide TPARHIY. Several binding studies were 
performed, namely ESI-MS, BLItz, and NMR. Each study was performed at both pH 5.5 
and pH 7.0 with H69 ΨΨΨ and H69 UUU. These studies revealed TARHIY binding to 
H69, and gave the apparent Kd values. The peptide showed moderate binding affinity 
(10-20 µM) with a Kd value close to that of a natural antibiotic, neomycin, binding to 
H69.187 However, curve fits for Kd determination were poor and our results imply more 
complex binding events than 1:1 interactions. 
The binding site was examined by 2D NMR, which suggested binding near C1914 and 
C1920. To the best of our knowledge, this is the first example of a small molecule 
interacting with the loop region of H69 for the isolated RNA. All of the methods 
complement each other, and the observed trends in Kd values were consistent. ESI-MS 
and BLItz studies showed there was no apparent selectivity between H69 ΨΨΨ and H69 
UUU.  
Growth assays showed that the phage with TARHIY decrease E. coli amplification, 
however, the difference from other sequences that are known fast growers was not 
significant, leaving the possibility of the selected peptide being a fast grower with 
moderate binding to the target. However, if complete growth inhibition is achieved, the 
peptides would never be selected. Therefore, TARHIY may further be optimized to 
enhance its binding affinity. 
Peptide TARHIY exhibited moderate binding affinity with Kd values comparable to 
those observed with neomycin binding to H69. Although selectivity was not achieved, the 
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peptide could be used to screen for ligands binding to the H69 loop region with higher 
affinity. In order to find a peptide selective for H69 ΨΨΨ, one may alter the selection 
conditions. Specific elution may be useful, but, for a target with a flexible structure such 
as H69, the resulting peptide may not be that selective. Another method that could be 
useful for improving the peptide selectivity is counter-selection by performing biopanning 
with H69 ΨΨΨ, followed by a secondary selection with H69 UUU or vice versa. Phage 
expressing TPARHIY was obtained 38 times out of 105 sequences from round 3. This 
sequence was dominant in the selection, suggesting that it is a fast grower, which was 
supported by the growth assay results.  
In this study, we used pH 5.5 buffer conditions, which was acidic compared to 
physiological buffers commonly used in phage display. The yield obtained at each round 
was significantly smaller (>10-fold) compared to selections from pH 7.0 conditions. Other 
than the pH, we used biopanning conditions corresponding to previous studies.118 At 
rounds 3 and 4, the incubation time was decreased from 2 to 0.5 h. Tight binders have 
high koff values, which means the dissociation takes longer than weak binders. Therefore, 
increasing the incubation time may help increase the affinity. 
In this study, ESI-MS and SPR results suggested the possibility of 1:2 stoichiometry of 
RNA:peptide binding. Also, NMR results showed binding at the loop region, which was 
not seen previously with neomycin, and may imply a different binding mode than the 
aminoglycosides. There is a possibility of multimeric binding, which leaves questions 
regarding selection of monomer peptides from phage display. The binding mode of the 
peptide to H69 was still not clear, which led to the following studies in Chapter 4, in 
which multimeric binding of the peptides was explored.  
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CHAPTER 4 – EXPLORING MULTIMERIC BINDING EFFECTS OF PEPTIDES  
4.1. Design of branched peptides 
In Chapter 3, peptide TPARHIY was selected from phage display, and a truncated 
variant TARHIY exhibited moderate binding affinity for the desired target H69. As 
mentioned in the previous section, a 2:1 binding stoichiometry of the peptide to H69 was 
observed in ESI-MS studies, which led us to the design of a dimer peptide. Also, the 
NMR spectra for H69 ΨΨΨ with TARHIY indicated two sites of H69 undergoing chemical 
environment changes, namely C1914 in the loop, and C1920 in the stem near the loop. 
An approximate distance between C1914 and C1920 using PyMOL is 2.5 nm, while the 
monomer peptide length using Chem3D is 2 nm. Phage from the Ph.D.-7 library have 
five copies of the peptide expressed on the pIII coat protein, leaving the possibility for 
multimeric binding of the peptide to H69. Previous studies showed that branched 
peptides could accommodate cell-penetrating ligands, thus increasing their potential 
antibacterial activity.132, 189-190 Previous studies have also shown that peptides may bind 
to their targets in a multimeric fashion,191 especially those identified from phage 
display.190 These studies demonstrated that peptides found from phage display had 
weaker binding affinity as a monomer compared to that of a multimer.132, 189, 191 
Scatchard analysis on monomer binding was performed to determine whether 
multimeric binding takes place (Figure 4.1). The binding ratio (Y) over peptide 
concentration ([L]) was plotted against the binding ratio (Y) of the bound RNA over total 
RNA concentration. For 1:1 binding mode, a linear plot is shown, which was not 
observed with our ESI-MS data. Two linear slopes were observed, indicating two binding 
modes. This could possibly explain the poor fitting for ESI-MS binding curves in Figure 
3.14. Scatchard analysis revealed possible 2:1 binding or >1 binding mode of monomer.  
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Figure 4.1. A Scatchard plot of H69 UUU binding to TARHIY is shown. 
 
Based on this idea discussed above, we designed a dimeric peptide (Figure 4.2). The 
peptide selected in Chapter 3 appeared 38 times out of 105 from sequencing analysis. 
The binding affinity of the peptide to H69 was moderate (10-20 µM), with little selectivity 
for modification status of H69. Our goal was to test if there is a multimeric binding effect 
of the peptide. The phage has a Ser-Gly-Gly-Gly linker that is connected to the 
randomized peptide on the N-terminus. In our study, we used β-Ala-β-Ala-β-Ala as a 
linker, which provides the same number of carbons in between the monomer and the 
branch, and one less amide group, allowing enhanced flexibility. A lysine residue was 
used as the branch point, because of the ability to continue peptide synthesis off the side 
chain. 
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Figure 4.2. An image showing the rationale of the project and the structure of the 
dimer peptide is given. 
 
4.2. Synthesis of branched peptides 
To synthesize a dimer peptide, lysine was selected as the branch point. Lysine has an 
ε-amino group from the side chain, allowing addition of the same or different amino acids 
onto each amino group by utilizing specific protecting groups on each amino group. For 
this part of the study, Fmoc-Lys(Fmoc)-OH was used to add on identical peptide 
sequences to the branch. Two sequences, TARHIY, the phage-selected sequence, and 
AAAAAA, a control sequence, were the peptide monomers used to generate the dimer. 
On the phage, there are three glycines and a serine at the C-terminus of the peptide 
connected to the pIII coat protein, which works as a spacer.192 In this study, I added 
three β-alanines (B), which are commonly used spacers (Scheme 4.1). Even with the 
spacers after the branch, the surface of the resin was likely too crowded, leading to a 
failed synthesis. After using a low-loading resin NovaSynTGR resin (0.31 mmol/g), I was 
able to obtain the desired products in good yield and purity (Figure 4.3). The peptides, 
(TARHIYBBB)2-K-NH2 (branched TARHIY, B1T) and (AAAAAABBB)2-K-NH2 (branched 
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AAAAAA, B1A), were generated by using standard Fmoc-solid phase peptide synthesis 
(SPPS).132 The synthesized peptides were purified with HPLC and characterized by 
MALDI-TOF MS.  
 
Scheme 4.1. Synthesis of branched peptides with the same side chains 
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Figure 4.3. MALDI-TOF spectrum (a) and HPLC trace (b) of B1T is shown.  
 
Also, to examine whether the N-terminus of the peptide is important for activity (i.e., 
RNA binding), we designed branched TARHIY analogues. The sequences that were 
designed are shown in Figure 4.4. For a) and b), Fmoc-Lys(Fmoc)-OH was used as the 
branch point, and for c) and d), Fmoc-Lys(ivDde)-OH was employed. The protecting 
group ivDde allowed attaching a different side chain (i.e., AAAAAABBB or YIHRATBBB) 
onto the ε-amino group (Scheme 4.2). The peptides were synthesized with standard 
Fmoc-solid phase peptide synthesis (SPPS) using NovaSynTGR resin, and three β-
alanines (B) were added as spacers. To determine the role of peptide monomer 
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orientation, (TARHIYBBB)(YIHRATBBB)-K-prG-NH2 (reverse dimer TY) was designed. 
Also, a propargylglycine (prG) was added on the C-terminus to facilitate further 
modification on structures of the peptide, such as addition of a dye or small molecule for 
further studies. For c) and d), the sequence TARHIYBBB was synthesized first with Boc-
Thr(Bzl)-OH on the ɑ-amino group, followed by ivDde deprotection with 5% hydrazine, 
followed by Fmoc synthesis to add AAAAABBB or YIHRATBBB on the ε-amino group. 
The synthesis was followed by purification by HPLC and characterization by MALDI-TOF 
MS. 
 
Figure 4.4. Structures of branched peptides with alkynyl groups are shown. The 
following peptides were generated: a) (TARHIYBBB)2-K-prG-NH2 (dimer TT), b) 
(TARHIYBBB)(AAAAAABBB)-K-prG-NH2 (dimer TA), c) (AAAAAABBB)2-K-prG-NH2 
(dimer AA), and d) (TARHIYBBB)(YIHRATBBB)-K-prG-NH2 (reverse dimer TY). 
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Scheme 4.2. Scheme of synthesis of branched peptides with different side chains 
 
 
4.3. Binding of RNA with branched peptides using MALDI-TOF 
To examine complex formation of branched peptides, binding studies with H69 were 
carried out. The complex was detected by MALDI-TOF although this method is only 
qualitative. To 2 μM of H69 in water was added 2 μM of peptide solution, and the mixture 
was spotted on a MALDI plate using 3-hydroxypicolinic acid (HPA) as a matrix. The 
branched peptides described above were tested, with both H69 ΨΨΨ and H69 UUU. 
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Although not quantitative, this method does provide evidence for formation of complexes 
with the dimer TT, dimer TA, and reverse dimer TY with H69 (Figure 4.5). Complexes 
with the control dimer AA were not observed. Further studies were required to confirm 
the binding. 
 
Figure 4.5. MALDI-TOF results for binding of dimer TT, dimer AA, dimer TA, and 
reverse dimer TY with H69 ΨΨΨ are shown. While complexes of dimer, dimer TA, and 
reverse dimer TY with H69 were observed, complexes of dimer AA with H69 ΨΨΨ 
were not detected by MALDI-TOF.   
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4.4. Binding of RNA with branched peptides using ESI-MS 
 To determine the binding affinity of peptide (TARHIYBBB)2-K-NH2 (branched peptide, 
B1T), ESI-MS was used. In this study, the binding was measured at 10 mM NH4OAc for 
both pH 5.5 and pH 7.0 conditions, 1 μM of H69 ΨΨΨ and H69 UUU, and the 
concentration of peptide varied from 0 to 100 μM. Unlike the monomer, there was no 
overlap between the peptide and RNA peaks (Figures 4.6 to 4.9). In this case, intensity 
of the (5-) charge state, which was highest, was used for quantification. In the previous 
chapter in which monomers were examined, (5-) charge state was used. From the 
apparent Kd values (Table 4.1) obtained from plots shown in Figure 4.10, it is found that 
the binding affinities towards H69 ΨΨΨ and H69 UUU have both increased at least 10-
fold, but no apparent selectivity was observed. 
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Figure 4.6. Representative ESI-MS results for B1T titration (pH 5.5) against H69 ΨΨΨ 
are shown. In the spectra, complexes of 1:1 (H69 UUU:peptide) binding ratios are 
observed. The experiments were performed in duplicate at 10 mM NH4OAc (pH 5.5). 
The expanded figures are displayed in Appendix E. 
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Figure 4.7. Representative ESI-MS results for B1T titration (pH 5.5) against H69 UUU 
are shown. In the spectra, complexes of 1:1 (H69 UUU:peptide) binding ratios are 
observed. The experiments were performed in duplicate at 10 mM NH4OAc (pH 5.5). 
The expanded figures are displayed in Appendix E. 
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Figure 4.8. Representative ESI-MS results for B1T titration (pH 7.0) against H69 ΨΨΨ 
are shown. In the spectra, complexes of 1:1 (H69 UUU:peptide) binding ratios are 
observed. The experiments were performed in duplicate at 10 mM NH4OAc (pH 7.0). 
The expanded figures are displayed in Appendix E. 
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Figure 4.9. Representative ESI-MS results for B1T titration (pH 7.0) against H69 UUU 
are shown. In the spectra, complexes of 1:1 (H69 UUU:peptide) binding ratios are 
observed. The experiments were performed in duplicate at 10 mM NH4OAc (pH 7.0). 
The expanded figures are displayed in Appendix E. 
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Figure 4.10. ESI-MS results for branched peptide B1T at 10 mM NH4OAc (pH 5.5 and 
pH 7.0) against H69 ΨΨΨ and H69 UUU. a) The titration curves for TARHIY bound to 
H69 ΨΨΨ and H69 UUU (y axis: binding ratio of at (5-) charge state) at different buffer 
conditions (pH 5.5 vs. pH 7.0) are shown. 
 
Table 4.1. Apparent dissociation constants (Kds) obtained from ESI-MS. 
 
 
Scatchard analysis on dimer binding was performed (Figure 4.11). The binding ratio 
(Y) over peptide concentration ([L]) was plotted against the binding ratio (Y) of the bound 
RNA over total RNA concentration. For the monomer, two linear slopes were observed, 
indicating two binding modes. Scatchard analysis revealed possible 2:1 binding or >1 
binding mode of monomer. For the dimer, one linear slope was observed, which 
indicates 1:1 binding mode.  
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Figure 4.11. A Scatchard plot of H69 UUU binding to dimer peptide is shown. 
 
4.5. Binding of RNA with branched peptides using BLItz 
As a label-free method to monitor binding interactions, BLItz was used for dimer 
studies. The dimer exhibited binding to H69, while the control dimer AA did not show 
binding. For dimer TT, the apparent dissociation constant obtained was comparable to 
that obtained by ESI-MS, which was 2.2 ± 0.1 μM for H69 ΨΨΨ and 3.9 ± 0.2 μM H69 
UUU at pH 7.0. In contrast, SPR experiments were not successful with the dimer. 
Apparent Kd values using steady state response units were obtained, but the 
dissociation curves had very poor fits. Representative data are shown in Figures 4.12 to 
4.14. By using BLItz, we were able to obtain the apparent Kd values for the fits. Dimer 
peptide concentrations varying from 0 to 100 μM in buffers were studied.  
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Figure 4.12. Representative BLItz results for branched peptide dimer TT titration at pH 
5.5 (20 mM cacodylate, 100 mM KCl, and 0.1% Tween-20) and pH 7.0 (20 mM 
HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ and 
H69 UUU. The curves shown in color correspond to measurements of a two-fold serial 
dilution of the peptide ligands over a concentration range of 0 to 100 μM. The curves in 
black correspond to global fits in 1:1 binding model. The experiments were performed 
in triplicate. The expanded figures are displayed in Appendix B. 
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Figure 4.13. Representative BLItz results for branched peptide dimer TA titration at pH 
5.5 (20 mM cacodylate, 100 mM KCl, and 0.1% Tween-20) and pH 7.0 (20 mM 
HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ and 
H69 UUU. The curves shown in color correspond to measurements of a two-fold serial 
dilution of the peptide ligands over a concentration range of 0 to 100 μM. The curves in 
black correspond to global fits in 1:1 binding model. The experiments were performed 
in duplicate. The expanded figures are displayed in Appendix B. 
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Figure 4.14. Representative BLItz results for branched peptide reverse dimer TY 
titration at pH 5.5 (20 mM cacodylate, 100 mM KCl, and 0.1% Tween-20) and pH 7.0 
(20 mM HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 
ΨΨΨ and H69 UUU. The curves shown in color correspond to measurements of a two-
fold serial dilution of the peptide ligands over a concentration range of 0 to 100 μM. 
The curves in black correspond to global fits in 1:1 binding model (R2>0.98). The 
experiments were performed in duplicated. The expanded figures are displayed in 
Appendix B. 
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Table 4.2. Rate constants (kon and koff) obtained from BLItz 
 
Evaluation of the kinetics of the binding events revealed similar kon and koff values of 
the dimers binding to H69 ΨΨΨ and H69 UUU at pH 5.5 and pH 7.0. The kon and koff 
values are given in Table 4.2. For all of the dimers, compared to the monomer, ~10-fold 
faster association and dissociation was observed. Dimer TT revealed ~100-fold faster 
association to H69 and ~10-fold slower dissociation at pH 5.5 compared to the monomer. 
If the binding interaction is through charge-charge interactions, it makes sense that the 
association rate would be higher compared to the monomer due to increased charge on 
the dimer. However, similar to the binding of TARHIY, poor fitting was observed, both for 
the sensograms (Figures 4.10 to 4.12 and Appendix B) and the rate constants (Table 
4.2), possibly implying the binding of TARHIY to H69 is not through 1:1 binding mode.  
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Table 4.3. Apparent dissociation constants (Kds) obtained from BLItz 
 
  
The apparent Kd value obtained for dimer TT binding to H69 was 2.5 ± 0.8 μM on 
average, which is in agreement with that obtained from ESI-MS (2.9 ± 0.8 μM on 
average). The apparent Kd value obtained with dimer TA was 13 ± 1 μM, which was 
comparable to the value of TARHIY obtained with other methods (16 ± 5 μM with ESI-
MS and 15 ± 2 μM with BLItz). The apparent Kd value obtained for the reverse dimer TY 
and H69 UUU was 36 ± 3 μM on average, which is 10-fold less than that of dimer TT, 
and 3-fold lower than dimer TA or monomer peptide TARHIY towards H69 UUU. For the 
dimer studies, dimer TA and reverse dimer were generated to see if the orientation of 
the monomer units was important. The decrease in apparent Kd value obtained with 
reverse dimer TY compared to dimer TT may indicate that the orientation of the peptide 
is likely important, and also suggests multimeric binding. 
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From previous Scatchard analysis of the ESI-MS results, the monomer exhibited 2 
different slopes, while the dimer exhibited 1 slope. This result implied that the dimer may 
go through a 1:1 binding mode with H69. Apparent dissociation constants obtained from 
ESI-MS or BLItz both showed improved binding with dimer TT, suggesting the dimer TT 
binds to H69 tighter than the monomer up to 10-fold. However, in the expanded BLItz 
binding curves in Appendix B, dimer TT also does not show a good 1:1 fitting. This may 
suggest that although 1 slope was obtained from Scatchard analysis for dimer TT, the 
binding may not be through a 1:1 binding mode. Possibly adding more data points may 
provide a better understanding of the data. Also, for the BLItz binding curves, for dimer 
TT against H69 ΨΨΨ at pH 5.5, when the peptide concentration is lower than 6.3 μM, 
the curves exhibited better fitting, while the curves did not exhibit decent fitting with H69 
UUU or H69 ΨΨΨ at pH 7.0. Dimer TY also exhibited better fitting for both H69 and 
buffer conditions at lower concentration, suggesting the peptide goes through a 1:1 
binding. However, a better binding analysis may be required to understand the binding 
mode. Also, molecular docking experiments may provide better understanding of the 
binding mode as well.  
4.6. NMR spectroscopy 
In Chapter 3, binding of peptide TARHIY to H69 was examined by NMR. Small 
changes in chemical shifts at C1914 and C1920 were observed in pH 5.5 buffer 
conditions. In Sections 4.4 and 4.5, binding of these dimer analogues to H69 was 
examined, and relative binding affinities were determined. In this section, binding of 
dimer TT, dimer TA, and reverse dimer TY to H69 UUU (at pH 5.5 and pH 7.0) and H69 
ΨΨΨ was examined by NMR, and ge-2D COSY was used to analyze JH5-H6 of the 
pyrimidines. Peaks were assigned based on previously reported values.47, 166 Through 
such studies, the binding site(s) of the peptides can be deduced. The samples were 
prepared as mentioned in Chapter 2.8. The samples were then given to Evan Jones 
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who obtained the NMR spectra on Bruker ADVANCE 700 MHz NMR (Billerica, MA) 
equipped with a TXI cryoprobe at 298K. 
Dimer TT binding to H69 was examined first since it is derived from two copies of the 
parent monomer peptide. For H69 UUU at pH 5.5, chemical shift changes were 
observed at C1909, C1914, U1917, C1920, and C1924, which suggests an overall 
conformational change of the RNA, not just the loop region as we observed with the 
monomer (Figure 4.15). For H69 ΨΨΨ at pH 5.5, the loop region was not resolved well, 
however, we were able to observe a change at C1924 in the stem region (Figure 4.16). 
This result was different from that obtained with the monomer, which showed a chemical 
shift change at C1920. For H69 UUU at pH 7.0, changes at C1914 and C1920 were 
observed, which was not observed with the monomer (Figure 4.17).  
 
Figure 4.15. Overlay of the NMR spectra for H69 UUU in the absence (black) or 
presence (grey) of dimer TT at pH 5.5. The concentrations of RNA and peptide were 
50 and 500 μM, respectively. The arrow indicates the chemical shift change and 
direction at C1914. The NMR spectra were obtained by Evan Jones. 
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Figure 4.16. Overlay of the NMR spectra for H69 ΨΨΨ in the absence (black) or 
presence (grey) of dimer TT at pH 5.5. The concentrations of RNA and peptide were 
50 and 500 μM, respectively. The arrow indicates the chemical shift change and 
direction at C1914. The NMR spectra were obtained by Evan Jones. 
  
Figure 4.17. Overlay of the NMR spectra for H69 UUU in the absence (black) or 
presence (grey) of dimer TT at pH 7.0. The concentrations of RNA and peptide were 
50 and 500 μM, respectively. The arrow indicates the chemical shift change and 
direction at C1914. The NMR spectra were obtained by Evan Jones. 
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Figure 4.18. Overlay of the NMR spectra for H69 UUU in the absence (black) or 
presence (grey) of dimer TA at pH 5.5. The concentrations of RNA and peptide were 
50 and 500 μM, respectively. The arrow indicates the chemical shift change and 
direction at C1914. The NMR spectra were obtained by Evan Jones. 
 
Figure 4.19. Overlay of the NMR spectra for H69 ΨΨΨ in the absence (black) or 
presence (grey) of dimer TA at pH 5.5. The concentrations of RNA and peptide were 
50 and 500 μM, respectively. The NMR spectra were obtained by Evan Jones. 
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Figure 4.20. Overlay of the NMR spectra for H69 UUU in the absence (black) or 
presence (grey) of dimer TA at pH 7.0. The concentrations of RNA and peptide were 
50 and 500 μM, respectively. The NMR spectra were obtained by Evan Jones. 
 
Figure 4.21. Overlay of the NMR spectra for H69 UUU in the absence (black) or 
presence (grey) of reverse dimer TY at pH 5.5. The concentrations of RNA and 
peptide were 50 and 500 μM, respectively. The arrow indicates the chemical shift 
change and direction at C1914. The NMR spectra were obtained by Evan Jones. 
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Figure 4.22. Overlay of the NMR spectra for H69 ΨΨΨ in the absence (black) or 
presence (grey) of reverse dimer TY at pH 5.5. The concentrations of RNA and 
peptide were 50 and 500 μM, respectively. The NMR spectra were obtained by Evan 
Jones. 
 
Figure 4.23. Overlay of the NMR spectra for H69 UUU in the absence (black) or 
presence (grey) of dimer TA at pH 7.0. The concentrations of RNA and peptide were 
50 and 500 μM, respectively. The NMR spectra were obtained by Evan Jones. 
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The dimer TT binding to H69 UUU exhibited different chemical shift patterns at pH 5.5 
and pH 7.0. It has been reported previously that Ψ enhances base stacking, although the 
global stabilities of H69 UUU and H69 ΨΨΨ are similar.185 Considering that all of the 
dissociation constants are similar at both buffer conditions, this difference implies that 
the binding modes of the peptides may differ. However, the overall change in H69 UUU 
at pH 5.5 with dimer TT implies that the binding of the dimer TT compared to the 
monomer may be more extensive, involving more contacts with the RNA. This result is 
also consistent with the tighter affinity relative to monomer, as determined by ESI-MS 
and BLItz.  
Dimer TA binding to H69 was examined next to determine the role of the dimer identity. 
For H69 UUU at pH 5.5, a small chemical shift change was observed at C1914 (0.02 
ppm) and U1915 (0.01 ppm) upon addition of the peptide, which was similar to that of 
the monomer (Figure 4.18). For H69 ΨΨΨ at pH 5.5, the loop region was not well 
resolved, however, we were able to observe a slight (0.01 ppm) chemical shift change at 
U1923, which is in the stem region (Figure 4.19). This was different from the result 
obtained with the monomer, which only showed a chemical shift change at C1920. For 
H69 UUU at pH 7.0, no change was observed, which was similar to the result with the 
monomer (Figure 4.20). Similarity of the binding affinities of dimer TA and monomer 
binding to H69 were observed in previous ESI-MS and BLItz studies as well, implying 
the branch moiety (AAAAAA) does not impact the interactions with the RNA. 
Reverse dimer TY binding to H69 was examined to determine whether the sequence 
orientation was important. For H69 UUU at pH 5.5, a chemical shift upfield was observed 
at C1914 (0.02 ppm), which was in a different direction from the monomer or dimer TT 
changes (Figure 4.21). This shows that the orientation of the peptide is important in the 
peptide binding to H69. For H69 ΨΨΨ at pH 5.5 (Figure 4.22) or H69 UUU at pH 7.0 
(Figure 4.23), no change was observed.  
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In Sections 4.4 and 4.5, binding studies have shown that in comparison to the 
monomer, affinity of dimer TT increased up to 10-fold, but the dimer TA was similar, and 
the reverse dimer TY had 3-fold lower binding. Although the binding affinities of the 
monomer to H69 under different buffer conditions were similar, the NMR studies have 
shown that H69 ΨΨΨ at pH 5.5 or H69 UUU at pH 7.0 spectra had little or no changes in 
the chemical shifts upon peptide binding. Previous NMR studies revealed that for H69 
ΨΨΨ, local base-stacking interactions exist with Ψ1911-A1919-A1918-Ψ1917-A1916-
Ψ1915, while in H69 UUU only A1916 and U1917 participate in base stacking.48, 166 
These results also agreed well with DMS probing and SHAPE analysis.178, 193 For H69 
ΨΨΨ, Ψ modifications were shown to enhance base stacking, yet through the 
modifications the global structure is altered compared to the unmodified RNA, which is 
overall thermodynamically destabilizing due to constraints on the loop structure.185  
 
Figure 4.24. A schematic description of residues of H69 that showed a change upon 
peptide binding are marked. 
 
Upon binding of dimer TT, both H69 ΨΨΨ and H69 UUU have shown changes in 
chemical shifts for C1914 and Ψ/U1915, which implies binding to the loop region. Also, 
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for both H69 ΨΨΨ and H69 UUU at pH 5.5, change at C1920, and C1924 were 
observed, which may imply that there is a change in the overall conformation upon 
binding. The differences between H69 ΨΨΨ and H69 UUU in binding to the dimer TT 
were the additional changes in chemical shift observed in H69 UUU. However, residues 
in the loop region of H69 ΨΨΨ did not resolve well (C1914 and Ψ1915), possibly due to 
the flexible structure on the 5'-side of the loop. Residue Ψ1917 was shown to have an 
interaction with A1912, which protects that residue from solvent exposure.185 At pH 5.5, 
the stem-closing base pairing of Ψ/U1911 and C1920 was shown to be destabilized for 
both H69 ΨΨΨ and H69 UUU.166 In contrast, H69 UUU displayed a continuous base-
stacking interaction at U1911-A1912-C1914-U1915. With H69 at pH 7.0, the dimer TT 
showed interaction to the loop residues C1914 and U1915. Although the binding studies 
with ESI-MS and BLItz have shown the binding affinities to be similar to each other, the 
binding patterns in NMR studies were different. It is possible that the relaxed structure of 
H69 UUU at pH 7.0 plays a role in the different binding interactions with the peptides.  
4.7. Conclusions 
Multivalent effects of the peptide were explored by synthesizing dimer TARHIY and 
derivatives. By designing a dimeric peptide utilizing lysine as a branching point and β-
alanine as a linker, we were able to synthesize a dimeric peptide. Binding studies with 
ESI-MS and BLItz showed that the dimer TT peptide has enhanced binding compared to 
the monomer, which was also shown through Scatchard analysis. The peptide dimer 
derivatives with AAAAAA exhibited similar binding to the monomer. Reverse dimer TY 
with reverse sequence YIHRAT instead of TARHIY showed decreased binding. Studies 
with reverse dimer TY support the idea that there may be multivalent binding of the 
peptide to H69 as well as the importance of the orientation of the peptide. However, 
there is room for improvement for the design of the peptides. The branching point and 
linkers do not exactly match the original design of the phage library, which raise some 
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questions on the dimeric peptide studies. The linker can also be modified by using 
PEGylated linkers, which would add more flexibility to the peptides, and also will be 
resistant to degradation. 
One important fact we learned from BLItz studies was that the binding of the dimer TT 
to H69 was ~100-fold faster in association and ~10-fold faster in dissociation compared 
to the monomer TARHIY. The binding mode of TARHIY to H69 was not very clear from 
Chapter 3. With the increase of charge with the dimeric structure, the faster 
association/dissociation may support the binding to be through charge-charge 
interactions. Although the dimer TT and reverse dimer TY have the same amino acid 
composition, the orientation of the charges make a difference in both binding affinity and 
rate constants, also supporting the importance of orientation. The data obtained with 
ESI-MS or BLItz studies showed poor fitting, which suggests the peptide interaction to 
H69 may not be through a simple 1:1 binding or conditions for the experiments may 
need optimization.  
The NMR spectra obtained with NMR have shown changes in the chemical shifts for 
the stem region residues, which indicate an overall conformation change of the RNA 
upon peptide binding (Figure 4.23). In the NMR studies, the orientation of the peptide 
was important for the dimeric peptide binding. Overall, the work in this chapter has 
revealed the importance of the orientation of peptide binding to H69, along with the 
multimeric binding. 
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Figure 4.25. A schematic figure of dimer TT and reverse dimer is shown.   
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CHAPTER 5 – Future directions and Summary  
5.1. Future directions 
5.1.1. Optimization of the branched peptide binding 
In Chapter 4, dimeric peptides were synthesized, and binding studies revealed 
enhanced binding of those peptides compared to the monomer. However, the design of 
the peptide can be improved by optimization of the structure. We used lysine as a 
branching point, which was also used in previous studies involving multimeric peptide 
syntheses.132, 189 However, these studies can only explore dimeric binding, while studies 
from Bastings et al. have shown studies with multimers including dimers, teteramers, 
and pentamers. 190 In their study, the dendrimeric branch was synthesized, followed by 
attaching the peptide of interest via native chemical ligation (NCL). Dendrimeric 
branches will help explore multimeric binding. Also, by adding a clickable moiety such as 
an azide or alkyne, along with multimers, other molecules can be attached to the peptide 
(i.e., fluorescent dyes or potent molecules with binding affinity or cell-penetrating activity).  
Also, the distance between the branch and peptide can be optimized. In our study, β-
alanine was incorporated as a linker. However, previous studies have used different 
linkers in between, such as polyethyleneglycol (PEG), aminohexanoic acid (Ahx), β-
alanine (β-Ala), or 2-(2-aminoethoxy)ethoxy (AEEAc).132, 189-190 Also, in the study by 
Hooks et al., methionine, lysine, and D-lysine were used as spacers that can avoid 
aggregation of the peptide sequences.132 Optimization of the linker length along with 
chemical properties may enhance binding affinity to H69. In order to find an optimal 
distance, PEGylated amino acids can be incorporated as linkers, with structures shown 
in Figure 5.1. Also, by changing the linker length between the branching point and 
TARHIY, the optimal linker length can be found, by adding PEG groups as spacers.194-195 
Addition of PEG or propargylglycine onto either C- or N-terminus will allow observation 
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of the effect of the functional groups on each terminus. Synthesis of TARHIY peptides 
with PEG linkers was completed.  
 
Figure 5.1. Structure of TARHIY peptides with PEG spacers is shown. The 
propargylglycines and PEG groups were added to either the N-terminus or the C-
terminus. 
 
5.1.2. Developing TARHIY as a probe for H69 loop region binding studies 
In Chapter 3, TARHIY exhibited binding for H69 in the loop region. This was not seen 
previously, which may lead to the development of a probe targeting the loop region of 
H69. Also, dimer TT exhibited enhanced binding to H69. The binding sites of dimer TT 
was determined by NMR in Chapter 4. Dimer TT was shown to primarily bind to the loop 
region with H69 UUU at pH 7.0 and H69 ΨΨΨ at pH 5.5, and to change the overall 
chemical shifts with H69 UUU at pH 5.5. Previous studies have shown that RRF 
interacts with H69 in the loop region, which then reduces H69 interactions important for 
the B2a intersubunit bridge of the 70S ribosome.32, 61, 186, 188 Aminoglycosides primarily 
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bind to H69 in the stem region, and the overall conformation changes upon binding. The 
interaction between H69 and RRF was shown to be disrupted upon binding of 
aminoglycosides, leading to inhibition of ribosome recycling.186 In this thesis work, 
peptide TARHIY was shown to bind to the loop region with moderate affinity. Attaching 
fluorescent labels to the peptide TARHIY or dimer TT will enable screening molecules 
binding to H69 in the loop region. Also, fluorescence resonance energy transfer (FRET) 
assays may be employed to monitor changes in H69 and RRF interactions upon 
molecule binding. 
5.1.3. Mapping of H69 with TARHIY analogues using ESI-MS 
A 29-nucleotide hairpin structured RNA, trans-activating response element (TAR) RNA 
(5′-GGCAGAUCUGAGCCUGGGAGCUCUCUGCC-3′), is found in 5'-end of nascent 
HIV-1 transcripts, which has an extinction coefficient of 268,900 L/mol•cm.195 Trans-
activating (Tat) protein (H2N-GRKKRRQRRRPP-NH2) is an arginine-rich motif, which 
has tight binding to TAR RNA, reported to bind to the bulge and loop region.195 The 
binding affinity is 0.7 µM, and this is a well-established system for RNA-protein binding 
studies.195 Rana et al. have selected heterochiral tripeptides binding to the bulge region 
using TAR lacking the bulge as a competitor using one-bead-one-compound (OBOC) 
assay.196 The tripeptide KkN exhibited tighter binding than Tat protein (0.4 µM), and Rkv 
exhibited weaker binding (10 µM).196 To find the binding region at the molecular level, 
ESI-MS mapping would be ideal. Among other biophysical methods used in this study, 
only NMR spectroscopy and ESI-MS only can monitor ligand binding sites on RNA at a 
molecular level. While NMR spectroscopy has a limitation of requiring a large amounts of 
the sample, ESI-MS only requires small amount of sample. In our NMR studies, although 
the binding affinities appeared to be similar, H69 ΨΨΨ and H69 UUU showed different 
patterns for binding dimer peptides. Furthermore, some peaks were difficult to observe 
due to the flexible nature of the H69 loop region. ESI-MS mapping may allow monitoring 
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of these flexible regions upon binding to peptides. Since the binding region is known for 
TAR RNA to Tat peptide, employing ESI-MS and establishing mapping methods with the 
tripeptides (KkN and Rkv) would be valuable. This approach could be used to detect 
binding regions of other peptides to target RNAs, such as H69. We could monitor 
binding of TARHIY or neomycin towards modified or unmodified variants of H69.197 
Currently, the mapping studies using ESI-MS are being done in the Rodgers’ lab. TAR 
RNA was prepared using T7 polymerase in vitro transcription, and the peptides were 
prepared using solid-phase peptide synthesis.  
 
Figure 5.2. Structures of TAR RNA and H69 UUU and peptides that can be employed 
for mapping studies are shown. 
 
5.2. Summary 
In order to find a ligand that can target H69 of the bacterial ribosome, in Chapter 3, 
phage display was performed in pH 5.5, and several peptides were selected. The 
selected peptides were synthesized, and a peptide TARHIY was selected by FID assay 
for further binding studies. The peptide TARHIY showed moderate binding to H69 
123 
 
 
employing ESI-MS and BLItz. However, the selected peptide TARHIY did not show 
selectivity towards a certain conformation or type of H69, although the peptide showed 
selectivity towards H69 over tRNAPhe. The binding site of peptide TARHIY was 
determined to be in the loop region of H69 employing NMR, which was not observed 
previously. 
In Chapter 4, analogues of dimers were synthesized and the binding of those to H69 
were studied. These studies have shown that the peptide TARHIY may be binding to 
H69 in a cooperative manner, shown in increased binding affinity with ESI-MS and BLItz, 
and change in conformation with a dimer that was monitored with NMR. Also, The dimer 
exhibited improved binding comparable to the binding affinity of neomycin. Based on our 
NMR studies, H69 UUU showed conformational changes upon dimeric binding, which 
were similar to that of neomycin binding to H69.  
In Chapter 5, dual binding of neomycin and peptide TARHIY were examined with 
MALDI-TOF and BLItz studies. Neomycin, a well-known aminoglycoside binds to H69 at 
the stem region. It was shown that there is a complex of neomycin, peptide TARHIY, and 
H69. However, although the primary binding sites have been shown to be different for 
the two ligands, when they are incubated together with H69, the binding events may not 
be independent from each other. Previous studies of Agris et al.187 have shown that 
neomycin may bind to H69 in a cooperative manner by changing the conformation of 
H69. The BLItz experiment has shown that the binding of neomycin and peptide TARHIY 
may not be independently binding to H69. This may imply although the primary binding 
sites are different, neomycin and peptide TARHIY may bind to H69 in a similar fashion 
by altering the conformation.  
Overall, a peptide sequence targeting H69 was identified from phage display, and 
using various methods, the peptide exhibited moderate binding. The peptide showed 
binding to the loop region of H69, which was not observed previously. A known 
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aminoglycoside neomycin binds to the stem region of H69, therefore, dual binding was 
explored by monitoring a complex formation with MALDI-TOF. Serial incubation then left 
dual binding of neomycin or peptide TARHIY to be questionable. Also, multimeric 
binding was observed with the peptide TARHIY, which was then studied with dimeric 
peptides, which showed enhanced binding. This result indicates that peptides selected 
using phage display may be useful parent sequences, however, whether the monomer is 
a tight binder itself or multimeric effects enhance the binding need to be considered.  
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APPENDIX A. MALDI-TOF RESULTS AND HPLC TRACES OF PEPTIDES USED IN 
THIS THESIS 
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Figure A1. MALDI-TOF spectrum (a) and HPLC trace (b) of STFTKSP is shown. 
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Figure A2. MALDI-TOF spectrum (a) and HPLC trace (b) of TPARHIY is shown. 
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Figure A3. MALDI-TOF spectrum (a) and HPLC trace (b) of SAPHHND is shown. 
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Figure A4. MALDI-TOF spectrum (a) and HPLC trace (b) of SRAHHIA is shown. 
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Figure A5. MALDI-TOF spectrum (a) and HPLC trace (b) of SHSLLHH is shown. 
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Figure A6. MALDI-TOF spectrum (a) and HPLC trace (b) of SLPTLTL is shown. 
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Figure A7. MALDI-TOF spectrum (a) and HPLC trace (b) of SILPYPY is shown. 
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Figure A8. MALDI-TOF spectrum (a) and HPLC trace (b) of HAIYPRH is shown. 
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Figure A9. MALDI-TOF spectrum (a) and HPLC trace (b) of NHWASPR is shown. 
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Figure A10. MALDI-TOF spectrum (a) and HPLC trace (b) of HITSTRY is shown. 
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Figure A11. MALDI-TOF spectrum (a) and HPLC trace (b) of FGHYHYA is shown. 
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Figure A12. MALDI-TOF spectrum (a) and HPLC trace (b) of SFVLPYY is shown. 
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Figure A13. MALDI-TOF spectrum (a) and HPLC trace (b) of SPPHHND is shown. 
 
 
 
 
 
139 
 
 
 
Figure A14. MALDI-TOF spectrum (a) and HPLC trace (b) of dimer TT is shown. 
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Figure A15. MALDI-TOF spectrum (a) and HPLC trace (b) of dimer TA is shown. 
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Figure A16. MALDI-TOF spectrum (a) and HPLC trace (b) of reverse dimer TY is shown. 
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Figure B1. Representative BLItz results for TARHIY titration at pH 5.5 (20 mM 
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 ΨΨΨ. Black lines represent 
the 1:1 fitting curve. 
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Figure B2. Representative BLItz results for TARHIY titration at pH 5.5 (20 mM 
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 UUU. Black lines represent 
the 1:1 fitting curve. 
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Figure B3. Representative BLItz results for TARHIY titration at pH 7.0 (20 mM HEPES-
KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ. Black lines 
represent the 1:1 fitting curve. 
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Figure B4. Representative BLItz results for TARHIY titration at pH 7.0 (20 mM HEPES-
KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 UUU. Black lines 
represent the 1:1 fitting curve. 
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Figure B5. Representative BLItz results for dimer TT titration at pH 5.5 (20 mM 
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 ΨΨΨ. Black lines represent 
the 1:1 fitting curve. 
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Figure B6. Representative BLItz results for dimer TT titration at pH 5.5 (20 mM 
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 UUU. Black lines represent 
the 1:1 fitting curve. 
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Figure B7. Representative BLItz results for dimer TT titration at pH 7.0 (20 mM HEPES-
KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ. Black lines 
represent the 1:1 fitting curve. 
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Figure B8. Representative BLItz results for dimer TT titration at pH 7.0 (20 mM HEPES-
KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 UUU. Black lines 
represent the 1:1 fitting curve. 
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Figure B9. Representative BLItz results for dimer TA titration at pH 5.5 (20 mM 
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 ΨΨΨ. Black lines represent 
the 1:1 fitting curve. 
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Figure B10. Representative BLItz results for dimer TA titration at pH 5.5 (20 mM 
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 UUU. Black lines represent 
the 1:1 fitting curve. 
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Figure B11. Representative BLItz results for dimer TA titration at pH 7.0 (20 mM 
HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ. Black 
lines represent the 1:1 fitting curve. 
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Figure B12. Representative BLItz results for dimer TA titration at pH 7.0 (20 mM 
HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 UUU. Black 
lines represent the 1:1 fitting curve. 
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Figure B13. Representative BLItz results for dimer TY titration at pH 5.5 (20 mM 
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 ΨΨΨ. Black lines represent 
the 1:1 fitting curve. 
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Figure B14. Representative BLItz results for dimer TY titration at pH 5.5 (20 mM 
cacodylate, 100 mM KCl, and 0.1% Tween-20) against H69 UUU. Black lines represent 
the 1:1 fitting curve. 
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Figure B15. Representative BLItz results for dimer TY titration at pH 7.0 (20 mM 
HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 ΨΨΨ. Black 
lines represent the 1:1 fitting curve. 
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Figure B16. Representative BLItz results for dimer TY titration at pH 7.0 (20 mM 
HEPES-KOH, 100 mM KCl, 5 mM MgCl2, and 0.1% Tween-20) against H69 UUU. Black 
lines represent the 1:1 fitting curve. 
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APPENDIX C. CHEMICAL SHIFT CHANGES OF H69 UPON PEPTIDE TITRATION 
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APPENDIX D. BUFFERS USED IN THIS THESIS STUDY 
Buffer A 
20 mM HEPES-KOH, pH 7.0, 100 mM KCl, 5 mM MgCl2, 5% glycerol, 0.1 mg/mL BSA 
with 0.1% (v/v) Tween-20  
Buffer B 
20 mM PBS, pH 5.5, 100 mM KCl, 5% glycerol, 0.1 mg/mL BSA with 0.1% (v/v) 
Tween-20 (buffer B) 
Binding buffer (pH 7.0) 
20 mM HEPES-KOH, pH 7.0, 100 mM KCl, 5 mM MgCl2, 5% glycerol, 0.1 mg/mL BSA  
Binding buffer (pH 5.5) 
20 mM PBS, pH 5.5, 100 mM KCl, 5% glycerol, 0.1 mg/mL BSA with 0.1% (v/v)  
ESI-MS buffer (pH 5.5 or pH 7.0) 
10 mM NH4OAc, 50% isopropanol 
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Figure E1. Expanded view of representative ESI-MS results for TARHIY titration (pH 
5.5) against H69 ΨΨΨ. 
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Figure E2. Expanded view of representative ESI-MS results for TARHIY titration (pH 
5.5) against H69 UUU. 
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Figure E3. Expanded view of representative ESI-MS results for TARHIY titration (pH 
7.0) against H69 ΨΨΨ. 
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Figure E4. Expanded view of representative ESI-MS results for TARHIY titration (pH 
7.0) against H69 UUU. 
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Figure E5. Expanded view of representative ESI-MS results for B1T titration (pH 5.5) 
against H69 ΨΨΨ. 
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Figure E6. Expanded view of representative ESI-MS results for B1T titration (pH 5.5) 
against H69 UUU. 
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Figure E7. Expanded view of representative ESI-MS results for B1T titration (pH 7.0) 
against H69 ΨΨΨ. 
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Figure E8. Expanded view of representative ESI-MS results for B1T titration (pH 7.0) 
against H69 UUU. 
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In the development of methods to peptides targeting helix 69 (H69) of 23S ribosomal 
RNA (rRNA) in bacterial ribosomes, phage display was employed at pH 5.5, a buffer 
condition previously reported to favor H69 in a closed conformation. After sequencing 
the selected phage, several peptides were chosen through sequence alignments, 
followed by preparation using solid phase peptide synthesis. The peptides were 
characterized by using matrix assisted laser desorption/ionization-time of flight (MALDI-
TOF) mass spectrometry and purified by high performance liquid chromatography 
(HPLC). A truncated peptide TARHIY was selected from fluorescence dye displacement 
(FID) assay. Through binding studies using electrospray ionization mass spectrometry 
(ESI-MS), surface plasmon resonance (SPR), biolayer interferometry (BLItz), and 
nuclear magnetic resonance (NMR), the binding of the peptide to H69 was quantified, 
and the, stoichiometries and interaction sites were determined. The peptide exhibited 
moderate binding affinity towards H69 (apparent Kd~10 µM) using ESI-MS, SPR, and 
BLItz, and the results from the various methods matched well. However, no differences 
in H69 affinities were observed under different buffer conditions and the RNA type (i.e., 
modified or unmodified) was not distinguished by the peptide. Data obtained from ESI-
MS suggested dimeric binding at higher concentrations, which was explored in the later 
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part of the research. The interaction site of the peptide towards H69 was explored using 
NMR, which indicated binding to the loop region of H69, which was not observed before. 
Although the desired selectivity towards H69 ΨΨΨ was not obtained, the selected 
peptide TARHIY exhibited moderate binding to H69 that can further be developed as a 
probe for H69 loop region. 
Multimeric binding of peptides to H69 was explored by using dimeric peptides. Dimeric 
peptides with the same or different sequences on amino groups of lysine were prepared 
using solid phase peptide synthesis. Improved binding affinities (apparent Kd~1 µM) of 
the dimer towards H69 (modified and unmodified variants) compared to the monomer 
peptide were observed by ESI-MS and BLItz. The binding affinity of the dimer TT was 
comparable to neomycin, a known aminoglycoside, while reverse dimer TY, exhibited 
decrease in binding affinity, suggesting the N-terminus plays an important role in binding, 
and that the 1:2 RNA:peptide complexes observed in ESI-MS spectra were not solely 
due to aggregation. An overall conformational change was observed with dimer TT using 
NMR, which was also comparable to neomycin. Further studies will help elucidate the 
actual binding mode of peptide TARHIY towards H69. These results suggest the 
possibility of multimeric binding should be taken into consideration with peptides 
selected from phage display. 
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